Christian W Hamm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/843806/publications.pdf

Version: 2024-02-01

793 papers 91,953 citations

107 h-index 289 g-index

843 all docs 843 docs citations

times ranked

843

51128 citing authors

#	Article	IF	CITATIONS
1	2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 2017, 38, 2739-2791.	2.2	5,142
2	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	2.2	5,034
3	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
4	ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2999-3054.	2.2	2,995
5	Universal Definition of Myocardial Infarction. Circulation, 2007, 116, 2634-2653.	1.6	2,755
6	Third Universal Definition of Myocardial Infarction. Circulation, 2012, 126, 2020-2035.	1.6	2,722
7	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	2.2	2,687
8	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 2006, 354, 1706-1717.	27.0	2,582
9	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	2.8	2,558
10	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	2.2	2,447
11	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
12	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	1.4	2,164
13	Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction. New England Journal of Medicine, 2006, 355, 1210-1221.	27.0	1,808
14	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. European Heart Journal, 2007, 28, 1598-1660.	2.2	1,699
15	Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 2015, 372, 1791-1800.	27.0	1,585
16	Guidelines for Percutaneous Coronary Interventions. European Heart Journal, 2005, 26, 804-847.	2.2	1,408
17	Circulating MicroRNAs in Patients With Coronary Artery Disease. Circulation Research, 2010, 107, 677-684.	4.5	1,121
18	Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia. New England Journal of Medicine, 1996, 335, 1333-1342.	27.0	1,042

#	Article	IF	CITATIONS
19	The Prognostic Value of Serum Troponin T in Unstable Angina. New England Journal of Medicine, 1992, 327, 146-150.	27.0	960
20	Emergency Room Triage of Patients with Acute Chest Pain by Means of Rapid Testing for Cardiac Troponin T or Troponin I. New England Journal of Medicine, 1997, 337, 1648-1653.	27.0	960
21	Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes. Circulation, 2003, 108, 1440-1445.	1.6	891
22	Soluble CD40 Ligand in Acute Coronary Syndromes. New England Journal of Medicine, 2003, 348, 1104-1111.	27.0	808
23	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine, 2012, 367, 1297-1309.	27.0	765
24	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2002, 23, 1809-1840.	2.2	764
25	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. Journal of the American College of Cardiology, 2007, 49, 1982-1988.	2.8	752
26	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. New England Journal of Medicine, 2013, 368, 1303-1313.	27.0	695
27	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	27.0	683
28	Benefit of Abciximab in Patients with Refractory Unstable Angina in Relation to Serum Troponin T Levels. New England Journal of Medicine, 1999, 340, 1623-1629.	27.0	668
29	How to use high-sensitivity cardiac troponins in acute cardiac care. European Heart Journal, 2012, 33, 2252-2257.	2.2	666
30	Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet, The, 2009, 373, 1190-1197.	13.7	649
31	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The. 2018. 392. 940-949.	13.7	555
32	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2019, 381, 1524-1534.	27.0	543
33	Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes. New England Journal of Medicine, 2013, 369, 999-1010.	27.0	539
34	Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 2014, 371, 1016-1027.	27.0	538
35	Recommendations for the use of cardiac troponin measurement in acute cardiac care. European Heart Journal, 2010, 31, 2197-2204.	2.2	533
36	Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. European Heart Journal, 2006, 27, 2775-2783.	2.2	530

#	Article	IF	Citations
37	2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Journal of Cardio-thoracic Surgery, 2017, 52, 616-664.	1.4	510
38	A Randomized Study of Coronary Angioplasty Compared with Bypass Surgery in Patients with Symptomatic Multivessel Coronary Disease. New England Journal of Medicine, 1994, 331, 1037-1043.	27.0	503
39	Effects of the Direct Lipoprotein-Associated Phospholipase A ₂ Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque. Circulation, 2008, 118, 1172-1182.	1.6	492
40	Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet, The, 2000, 356, 1895-1897.	13.7	485
41	Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet, The, 1999, 354, 1757-1762.	13.7	480
42	Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes. Circulation, 2002, 105, 1446-1452.	1.6	472
43	Circumferential Pulmonary Vein Isolation With the Cryoballoon Technique. Journal of the American College of Cardiology, 2008, 52, 273-278.	2.8	458
44	Bivalirudin Started during Emergency Transport for Primary PCI. New England Journal of Medicine, 2013, 369, 2207-2217.	27.0	443
45	Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet, The, 2008, 372, 537-546.	13.7	431
46	Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Nonâ€"ST-Segment-Elevation Acute Coronary Syndromes. Circulation, 2001, 104, 2767-2771.	1.6	411
47	Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart, 2005, 92, 843-849.	2.9	398
48	Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. Journal of the American College of Cardiology, 2000, 35, 1535-1542.	2.8	384
49	Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery. European Heart Journal, 2007, 28, 2456-2464.	2.2	378
50	Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2007, 297, 43.	7.4	368
51	Serum Level of the Antiinflammatory Cytokine Interleukin-10 Is an Important Prognostic Determinant in Patients With Acute Coronary Syndromes. Circulation, 2003, 107, 2109-2114.	1.6	354
52	Perioperative Results and Complications inÂ15,964 Transcatheter Aortic Valve Replacements. Journal of the American College of Cardiology, 2015, 65, 2173-2180.	2.8	349
53	A Classification of Unstable Angina Revisited. Circulation, 2000, 102, 118-122.	1.6	348
54	The German Aortic Valve Registry (GARY): in-hospital outcome. European Heart Journal, 2014, 35, 1588-1598.	2.2	304

#	Article	IF	Citations
55	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ, The, 2014, 348, g3859-g3859.	6.0	291
56	Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet, The, 2013, 382, 1981-1992.	13.7	286
57	Clinical Outcome 2 Years After Intracoronary Administration of Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction. Circulation: Heart Failure, 2010, 3, 89-96.	3.9	266
58	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2018, 53, 34-78.	1.4	261
59	Value of Serial Troponin T Measures for Early and Late Risk Stratification in Patients With Acute Coronary Syndromes. Circulation, 1998, 98, 1853-1859.	1.6	259
60	2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2015, 10, 1024-1094.	3.2	251
61	European expert consensus on rotational atherectomy. EuroIntervention, 2015, 11, 30-36.	3.2	247
62	N-Terminal Pro–B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes. Circulation, 2004, 110, 3206-3212.	1.6	246
63	Mechanisms of stress (Takotsubo) cardiomyopathy. Nature Reviews Cardiology, 2010, 7, 187-193.	13.7	233
64	Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. European Heart Journal, 2012, 33, 2001-2006.	2.2	233
65	Rotational Atherectomy Does Not Reduce Recurrent In-Stent Restenosis. Circulation, 2002, 105, 583-588.	1.6	230
66	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet, The, 2010, 376, 517-523.	13.7	222
67	5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions. Journal of the American College of Cardiology, 2010, 55, 1093-1101.	2.8	218
68	Current Status of Bioresorbable ScaffoldsÂin the Treatment of CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2014, 64, 2541-2551.	2.8	218
69	Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid. Circulation, 2008, 118, 1705-1712.	1.6	210
70	Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes. Journal of the American College of Cardiology, 2005, 45, 229-237.	2.8	200
71	Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. European Heart Journal, 2010, 31, 1701-1707.	2.2	199
72	Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2016, 315, 1591.	7.4	190

#	Article	IF	CITATIONS
73	Angiographic Findings in Patients With Refractory Unstable Angina According to Troponin T Status. Circulation, 1999, 100, 1509-1514.	1.6	188
74	Pulmonary Vein Diameter Reduction After Radiofrequency Catheter Ablation for Paroxysmal Atrial Fibrillation Evaluated by Contrast-Enhanced Three-Dimensional Magnetic Resonance Imaging. Circulation, 2003, 107, 845-850.	1.6	188
75	A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention, 2005, 1, 58-65.	3.2	186
76	Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. European Heart Journal, 2015, 36, 369-376.	2.2	182
77	Magnetic resonance to assess the aortic valve area in aortic stenosis. Journal of the American College of Cardiology, 2003, 42, 519-526.	2.8	178
78	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. European Respiratory Journal, 2017, 49, 1602409.	6.7	178
79	Biochemical evidence of platelet activation in patients with persistent unstable angina. Journal of the American College of Cardiology, 1987, 10, 998-1004.	2.8	177
80	Cardiac Troponin Elevations in Patients Without Acute Coronary Syndrome. Circulation, 2002, 106, 2871-2872.	1.6	177
81	Comparison of Diagnostic Value of a Novel Noninvasive Coronary Computed Tomography Angiography Method Versus Standard Coronary Angiography for Assessing Fractional Flow Reserve. American Journal of Cardiology, 2014, 114, 1303-1308.	1.6	171
82	Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: Results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac Magnetic Resonance Imaging substudy. American Heart Journal, 2009, 157, 541-547.	2.7	168
83	Bone marrow-derived cells contribute to infarct remodelling. Cardiovascular Research, 2006, 71, 661-671.	3.8	167
84	Effect of Early, Pre-Hospital Initiation of High Bolus Dose Tirofiban in Patients With ST-Segment Elevation Myocardial Infarction on Short- and Long-Term Clinical Outcome. Journal of the American College of Cardiology, 2010, 55, 2446-2455.	2.8	164
85	N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. American Heart Journal, 2004, 148, 612-620.	2.7	156
86	Incremental value of high-sensitive troponin T in addition to the revised cardiac index for peri-operative risk stratification in non-cardiac surgery. European Heart Journal, 2013, 34, 853-862.	2.2	153
87	The German Aortic Valve Registry: 1-year results from 13 680 patients with aortic valve diseaseâ€. European Journal of Cardio-thoracic Surgery, 2014, 46, 808-816.	1.4	151
88	The future of transcatheter aortic valve implantation. European Heart Journal, 2016, 37, 803-810.	2.2	137
89	Prognostic Value of Placental Growth Factor in Patients With Acute Chest Pain. JAMA - Journal of the American Medical Association, 2004, 291, 435.	7.4	136
90	Human hibernating myocardium is jeopardized by apoptotic and autophagic cell death. Journal of the American College of Cardiology, 2004, 43, 2191-2199.	2.8	133

#	Article	IF	Citations
91	2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease. Revista Espanola De Cardiologia (English Ed), 2018, 71, 110.	0.6	131
92	Door-to-implantation time of extracorporeal life support systems predicts mortality in patients with out-of-hospital cardiac arrest. Clinical Research in Cardiology, 2013, 102, 661-669.	3.3	129
93	Coronary Computed Tomographic Prediction Rule for Time-Efficient Guidewire Crossing Through ChronicÂTotalÂOcclusion. JACC: Cardiovascular Interventions, 2015, 8, 257-267.	2.9	129
94	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. European Heart Journal, 2014, 35, 2295-2302.	2.2	128
95	Novel rat model reveals important roles of \hat{l}^2 -adrenoreceptors in stress-induced cardiomyopathy. International Journal of Cardiology, 2013, 168, 1943-1950.	1.7	127
96	Improved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome. American Heart Journal, 2011, 162, 81-88.	2.7	125
97	Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. European Heart Journal, 2005, 26, 1023-1030.	2.2	124
98	Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet, The, 2014, 384, 1187-1195.	13.7	123
99	Abnormalities in intracellular Ca2+ regulation contribute to the pathomechanism of Tako-Tsubo cardiomyopathy. European Heart Journal, 2009, 30, 2155-2164.	2.2	120
100	Immunohistological basis of the late gadolinium enhancement phenomenon in tako-tsubo cardiomyopathy. European Heart Journal, 2009, 30, 1635-1642.	2.2	116
101	Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet, The, 2001, 358, 1533-1538.	13.7	114
102	Relation of N-Terminal Pro–B-Type Natriuretic Peptide to Severity of Valvular Aortic Stenosis. American Journal of Cardiology, 2004, 94, 740-745.	1.6	114
103	The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II). European Heart Journal, 2007, 28, 433-442.	2.2	113
104	MEDAFI-Trial (Micro-embolization during ablation of atrial fibrillation): comparison of pulmonary vein isolation using cryoballoon technique vs. radiofrequency energy. Europace, 2011, 13, 37-44.	1.7	112
105	Prognostic Significance of Angiogenic Growth Factor Serum Levels in Patients With Acute Coronary Syndromes. Circulation, 2003, 107, 524-530.	1.6	111
106	Electrocardiographic and further predictors for permanent pacemaker requirement after transcatheter aortic valve implantation. Europace, 2010, 12, 1188-1190.	1.7	111
107	A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. Journal of the American College of Cardiology, 2003, 42, 1360-1369.	2.8	108
108	Rapid Angiographic Progression of Coronary Artery Disease in Patients With Elevated Lipoprotein(a). Circulation, 1995, 91, 948-950.	1.6	108

#	Article	IF	Citations
109	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, The, 2013, 382, 605-613.	13.7	105
110	Open issues in transcatheter aortic valve implantation. Part 2: procedural issues and outcomes after transcatheter aortic valve implantation. European Heart Journal, 2014, 35, 2639-2654.	2.2	105
111	Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. European Heart Journal, 2010, 31, 35-49.	2.2	103
112	Conscious Sedation Versus GeneralÂAnesthesia in TranscatheterÂAortic ValveÂReplacement. JACC: Cardiovascular Interventions, 2018, 11, 567-578.	2.9	102
113	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. Journal of the American College of Cardiology, 2019, 74, 2223-2234.	2.8	101
114	Rapid Deployment Versus Conventional Bioprosthetic Valve Replacement for Aortic Stenosis. Journal of the American College of Cardiology, 2018, 71, 1417-1428.	2.8	100
115	Elevated Placental Growth Factor Levels Are Associated With Adverse Outcomes at Four-Year Follow-Up in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2006, 47, 307-311.	2.8	97
116	German Aortic Valve Score: a new scoring system for prediction of mortality related to aortic valve procedures in adults. European Journal of Cardio-thoracic Surgery, 2013, 43, 971-977.	1.4	97
117	P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. Thrombosis and Haemostasis, 2016, 116, 369-378.	3.4	97
118	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. JAMA Cardiology, 2019, 4, 1092.	6.1	97
119	Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY). European Heart Journal, 2019, 40, 1323-1330.	2.2	97
120	Evaluation of a Rapid Whole Blood ELISA for Quantification of Troponin I in Patients with Acute Chest Pain. Clinical Chemistry, 1999, 45, 1789-1796.	3.2	96
121	Open issues in transcatheter aortic valve implantation. Part 1: patient selection and treatment strategy for transcatheter aortic valve implantation. European Heart Journal, 2014, 35, 2627-2638.	2.2	96
122	Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2016, 35, 591-596.	0.6	96
123	Extracorporeal life support in cardiovascular patients with observed refractory in-hospital cardiac arrest is associated with favourable short and long-term outcomes: A propensity-matched analysis. European Heart Journal: Acute Cardiovascular Care, 2016, 5, 13-22.	1.0	95
124	Challenges of coronary angiography and intervention in patients previously treated by TAVI. Clinical Research in Cardiology, 2015, 104, 632-639.	3.3	93
125	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. European Heart Journal, 2020, 41, 3533-3545.	2.2	93
126	Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 63, 619-629.	2.8	92

#	Article	IF	CITATIONS
127	Incidence and outcome of peri-procedural transcatheter heart valve embolization and migration: the TRAVEL registry (TranscatheteR HeArt Valve EmboLization and Migration). European Heart Journal, 2019, 40, 3156-3165.	2.2	92
128	Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention, 2016, 12, 1239-1245.	3.2	92
129	Determination of arterial compliance using blood pressure waveform analysis with the CR-2000 systemReliability, repeatability, and establishment of normal values for healthy European population—the seven European sites study (SESS). American Journal of Hypertension, 2005, 18, 65-71.	2.0	91
130	Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival. European Heart Journal, 2014, 35, 1275-1283.	2.2	91
131	Sex Differences in Percutaneous Coronary Intervention—Insights From the Coronary Angiography and PCI Registry of the German Society of Cardiology. Journal of the American Heart Association, 2017, 6, .	3.7	89
132	Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events. JAMA Cardiology, 2016, 1, 425.	6.1	88
133	TAVI for low-flow, low-gradient severe aortic stenosis with preserved or reduced ejection fraction: a subgroup analysis from the German Aortic Valve Registry (GARY). EuroIntervention, 2014, 10, 850-859.	3.2	87
134	Release Kinetics of Circulating Muscle-Enriched MicroRNAs in Patients Undergoing Transcoronary Ablation of Septal Hypertrophy. Journal of the American College of Cardiology, 2013, 62, 992-998.	2.8	86
135	Intracoronary infusion of bone marrow-derived mononuclear cells abrogates adverse left ventricular remodelling post-acute myocardial infarction: insights from the reinfusion of enriched progenitor cells and infarct remodelling in acute myocardial infarcti. European Journal of Heart Failure, 2009, 11, 973-979.	7.1	85
136	Use and Outcomes of Multivessel Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock (from the EHS-PCI Registry). American Journal of Cardiology, 2012, 109, 941-946.	1.6	84
137	Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial. Journal of Cardiovascular Translational Research, 2014, 7, 91-100.	2.4	84
138	\hat{l}^2 -Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 872-881.	2.2	84
139	A mouse model reveals an important role for catecholamineâ€induced lipotoxicity in the pathogenesis of stressâ€induced cardiomyopathy. European Journal of Heart Failure, 2013, 15, 9-22.	7.1	83
140	Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. European Heart Journal, 2014, 35, 2460-2467.	2.2	80
141	Cryoballoon ablation of paroxysmal atrial fibrillation: 5-year outcome after single procedure and predictors of success. Europace, 2013, 15, 1143-1149.	1.7	79
142	Arterial Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroIntervention, 2005, 1, 147-56.	3.2	79
143	Preprocedural coronary CT angiography significantly improves success rates of PCI for chronic total occlusion. International Journal of Cardiovascular Imaging, 2013, 29, 1819-1827.	1.5	75
144	Noninvasive estimation of regurgitant flow rate and volume in patients with mitral regurgitation by doppler color mapping of accelerating flow field. Journal of the American College of Cardiology, 1993, 21, 374-383.	2.8	74

#	Article	IF	Citations
145	Acute Coronary Syndrome. Circulation, 2004, 109, 565-567.	1.6	74
146	Euro Heart Survey 2009 Snapshot: regional variations in presentation and management of patients with AMI in 47 countries. European Heart Journal: Acute Cardiovascular Care, 2013, 2, 359-370.	1.0	74
147	New Serum Markers for Acute Myocardial Infarction. New England Journal of Medicine, 1994, 331, 607-608.	27.0	73
148	Activated cell survival cascade protects cardiomyocytes from cell death in Tako-Tsubo cardiomyopathy. European Journal of Heart Failure, 2009, 11, 758-764.	7.1	73
149	Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. Journal of the American College of Cardiology, 1994, 23, 1397-1404.	2.8	72
150	Expression profiling of cardiac genes in Tako-Tsubo cardiomyopathy: Insight into a new cardiac entity. Journal of Molecular and Cellular Cardiology, 2008, 44, 395-404.	1.9	72
151	Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. American Heart Journal, 2012, 163, 768-776.e2.	2.7	72
152	Decreased Pulmonary Perfusion in Pulmonary Vein Stenosis After Radiofrequency Ablation. Chest, 2004, 126, 428-437.	0.8	71
153	Trends in practice and outcomes from 2011 to 2015 for surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42Â776 patients. European Journal of Cardio-thoracic Surgery, 2018, 53, 552-559.	1.4	71
154	Pacemaker implantation after TAVI: predictors of AV block persistence. Clinical Research in Cardiology, 2018, 107, 60-69.	3.3	71
155	Incidence and Predictors of Target Vessel Revascularization and Clinical Event Rates of the Sirolimus-Eluting Coronary Stent (Results from the Prospective Multicenter German Cypher Stent) Tj ETQq $1\ 1\ 0$.	78 4.3 14 r _{	gBT6Øverloc
156	Prior Coronary Artery Bypass Graft Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 343-351.	2.9	69
157	Use of automatic exposure control in multislice computed tomography of the coronaries: comparison of 16-slice and 64-slice scanner data with conventional coronary angiography. Heart, 2007, 93, 1040-1043.	2.9	68
158	Treatment of Aortocoronary Vein Graft Lesions With Membrane-Covered Stents. Circulation, 2000, 102, 2024-2027.	1.6	67
159	Pulmonary Vein Stenting for the Treatment of Acquired Severe Pulmonary Vein Stenosis after Pulmonary Vein Isolation: Clinical Implications after Longâ€Term Followâ€Up of 4 Years. Journal of Cardiovascular Electrophysiology, 2009, 20, 251-257.	1.7	67
160	Predictors of hospital mortality in the elderly undergoing percutaneous coronary intervention for acute coronary syndromes and stable angina. International Journal of Cardiology, 2011, 151, 164-169.	1.7	66
161	Invasive Optimization of Cardiac Resynchronization Therapy: Role of Sequential Biventricular and Left Ventricular Pacing. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 754-761.	1.2	64
162	N-Terminal B-Type Natriuretic Peptide Assessment Provides Incremental Prognostic Information in Patients With Acute Coronary Syndromes and Normal Troponin T Values Upon Admission. Journal of the American College of Cardiology, 2008, 51, 1188-1195.	2.8	64

#	Article	IF	CITATIONS
163	A Model for Predicting Mortality in Acute ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2010, 3, 414-422.	3.9	64
164	Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI. Journal of the American College of Cardiology, 2014, 64, 2563-2571.	2.8	64
165	Coronary CT angiography-derived fractional flow reserve correlated with invasive fractional flow reserve measurements – initial experience with a novel physician-driven algorithm. European Radiology, 2015, 25, 1201-1207.	4.5	63
166	Impact of the COVID-19 pandemic on cardiovascular mortality and catherization activity during the lockdown in central Germany: an observational study. Clinical Research in Cardiology, 2021, 110, 292-301.	3.3	63
167	Analytical performance and clinical application of a new rapid bedside assay for the detection of serum cardiac troponin I. Clinical Chemistry, 1998, 44, 1925-1930.	3.2	62
168	Contractile response and mitral regurgitation after temporary interruption of long-term cardiac resynchronization therapy. European Heart Journal, 2006, 27, 187-192.	2.2	62
169	Bivalirudin Versus Heparin With or WithoutÂGlycoprotein IIb/IIIa Inhibitors inÂPatients With STEMI Undergoing PrimaryÂPercutaneous Coronary Intervention. Journal of the American College of Cardiology, 2015, 65, 27-38.	2.8	62
170	Comparison of Saruplase and Alteplase in Acute Myocardial Infarction. American Journal of Cardiology, 1997, 79, 727-732.	1.6	61
171	Prehospital testing for troponin T in patients with suspected acute myocardial infarction. American Heart Journal, 1999, 138, 45-48.	2.7	61
172	Incidence and Clinical Impact of Stroke Complicating Transcatheter Aortic Valve Implantation: Results From the $\langle scp \rangle G \langle scp \rangle erman \langle scp \rangle TAVI \langle scp \rangle egistry. Catheterization and Cardiovascular Interventions, 2016, 88, 644-653.$	1.7	61
173	Outcome after transvascular transcatheter aortic valve implantation in 2016. European Heart Journal, 2018, 39, 667-675.	2.2	61
174	Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. European Heart Journal, 2019, 40, 2432-2440.	2.2	61
175	The ACURATE neo TranscatheterÂHeartÂValve. JACC: Cardiovascular Interventions, 2018, 11, 1721-1729.	2.9	60
176	Use and impact of intra-aortic balloon pump on mortality in patients with acute myocardial infarction complicated by cardiogenic shock: results of the Euro Heart Survey on PCI. EuroIntervention, 2011, 7, 437-441.	3.2	60
177	Transcatheter Aortic Valve ReplacementÂWith Next-Generation Self-Expanding Devices. JACC: Cardiovascular Interventions, 2019, 12, 433-443.	2.9	59
178	Efficacy of high dose intravenous heparin for treatment of left ventricular thrombi with high embolic risk. Journal of the American College of Cardiology, 1994, 24, 1305-1309.	2.8	58
179	Repeated Catheter Ablation of Atrial Fibrillation. Circulation Journal, 2013, 77, 2271-2279.	1.6	58
180	Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease. European Respiratory Journal, 2018, 52, 1800458.	6.7	57

#	Article	IF	CITATIONS
181	Angina, "Normal―Coronary Angiography, and Vascular Dysfunction: Risk Assessment Strategies. PLoS Medicine, 2007, 4, e12.	8.4	56
182	Diagnostic accuracy of computed tomography angiography for the detection of coronary artery disease in patients referred for transcatheter aortic valve implantation. Clinical Research in Cardiology, 2015, 104, 471-480.	3.3	56
183	Quality of Life After Transcatheter AorticÂValve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 2541-2554.	2.9	55
184	Impact of new pacemaker implantation following surgical and transcatheter aortic valve replacement on 1-year outcome. European Journal of Cardio-thoracic Surgery, 2020, 57, 151-159.	1.4	55
185	New biochemical markers for myocardial cell injury. Current Opinion in Cardiology, 1995, 10, 355-360.	1.8	54
186	Laser angioplasty of restenosed coronary stents: results of a multicenter surveillance trial. Journal of the American College of Cardiology, 1999, 34, 25-32.	2.8	54
187	Effects of gold coating of coronary stents on neointimal proliferation following stent implantation. American Journal of Cardiology, 2002, 89, 801-805.	1.6	54
188	Fiveâ€year longâ€term clinical followâ€up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with <i>de novo</i> coronary artery lesions: The SPIRIT FIRST trial. Catheterization and Cardiovascular Interventions, 2010, 75, 997-1003.	1.7	54
189	In-hospital outcome of transcatheter vs. surgical aortic valve replacement in patients with aortic valve stenosis: complete dataset of patients treated in 2013 in Germany. Clinical Research in Cardiology, 2016, 105, 553-559.	3.3	54
190	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. Pulmonary Circulation, 2018, 8, 1-6.	1.7	54
191	One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The) Tj ETQq1 :	l 0.784314	rgBT Overlo
192	Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction. American Journal of Cardiology, 1988, 61, 966-970.	1.6	52
193	Intravascular Therapeutic Ultrasound Thrombolysis in Acute Myocardial Infarctions. American Journal of Cardiology, 1997, 80, 200-204.	1.6	52
194	Cardiac Biomarkers for Rapid Evaluation of Chest Pain. Circulation, 2001, 104, 1454-1456.	1.6	52
195	Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. European Heart Journal, 2009, 30, 2575-2583.	2.2	52
196	Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Research in Cardiology, 2012, 107, 261.	5.9	52
197	Complications of transcatheter aortic valve implantation (TAVI): how to avoid and treat them. Heart, 2015, 101, 900-908.	2.9	52
198	Trends in aortic valve replacement in Germany in 2015: transcatheter versus isolated surgical aortic valve repair. Clinical Research in Cardiology, 2017, 106, 411-419.	3.3	52

#	Article	IF	CITATIONS
199	Influence of heart rate and phase of the cardiac cycle onÂthe occurrence of motion artifact in dual-source CT angiography of the coronary arteries. Journal of Cardiovascular Computed Tomography, 2012, 6, 91-98.	1.3	51
200	Release Kinetics of Inflammatory Biomarkers in a Clinical Model of Acute Myocardial Infarction. Circulation Research, 2015, 116, 867-875.	4.5	51
201	Recanalization of Total Coronary Occlusions Using a Laser Guidewire (The European TOTAL) Tj ETQq1 1 0.78431	4 rgBT /O	verlock 10 Tf
202	Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. American Heart Journal, 2005, 149, 402-407.	2.7	50
203	Incidence and Clinical Impact of Stroke Complicating Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 362-369.	3.9	50
204	Soluble fms-Like Tyrosine Kinase-1 and Endothelial Adhesion Molecules (Intercellular Cell Adhesion) Tj ETQq0 0 0 Reduction After Renal Sympathetic Denervation. Hypertension, 2014, 63, 984-990.	rgBT /Ove 2.7	erlock 10 Tf 5 50
205	Mammographic detection of breast arterial calcification as an independent predictor of coronary atherosclerotic disease in a single ethnic cohort of African American women. Atherosclerosis, 2015, 242, 218-221.	0.8	50
206	Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study. European Heart Journal, 2008, 29, 1127-1135.	2.2	49
207	Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clinical Research in Cardiology, 2014, 103, 141-148.	3.3	49
208	cAMP controls the restoration of endothelial barrier function after thrombin-induced hyperpermeability via Rac1 activation. Physiological Reports, 2014, 2, e12175.	1.7	49
209	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10Â854 patients from the CHAMPION PHOENIX trial. European Heart Journal, 2018, 39, 4112-4121.	2.2	49
210	Influence of Sample Type and Storage Conditions on Soluble CD40 Ligand Assessment. Clinical Chemistry, 2006, 52, 888-891.	3.2	48
211	Clinical impact of a novel three-dimensional electrocardiographic imaging for non-invasive mapping of ventricular arrhythmiasa prospective randomized trial. Europace, 2015, 17, 591-597.	1.7	48
212	Percutaneous Pulmonary Vein Stenting for the Treatment of Severe Stenosis After Pulmonary Vein Isolation. Journal of Cardiovascular Electrophysiology, 2005, 16, 1180-1188.	1.7	47
213	Cangrelor With and Without GlycoproteinÂllb/Illa Inhibitors inÂPatientsÂUndergoing PercutaneousÂCoronary Intervention. Journal of the American College of Cardiology, 2017, 69, 176-185.	2.8	47
214	Native T1 mapping and extracellular volume fraction measurement for assessment of right ventricular insertion point and septal fibrosis in chronic thromboembolic pulmonary hypertension. European Radiology, 2017, 27, 1980-1991.	4.5	47
215	Five-year outcome in 18 010 patients from the German Aortic Valve RegistryÂ. European Journal of Cardio-thoracic Surgery, 2021, 60, 1139-1146.	1.4	47
216	Six-month clinical and angiographic outcome after successful excimer laser angioplasty for in-stent restenosis. Journal of the American College of Cardiology, 2000, 36, 69-74.	2.8	46

#	Article	IF	Citations
217	Qualityâ€ofâ€Life in Patients with Paroxysmal Atrial Fibrillation After Catheter Ablation:. PACE - Pacing and Clinical Electrophysiology, 2003, 26, 678-684.	1.2	46
218	Detection of Myocardial Injury by CMR After Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2014, 64, 349-357.	2.8	46
219	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. European Heart Journal, 2017, 38, 3493-3502.	2.2	46
220	Recanalization of chronic, totally occluded coronary arteries by new angioplasty systems. American Journal of Cardiology, 1990, 66, 1459-1463.	1.6	45
221	Difficulties with oral platelet glycoprotein Ilb/IIIa receptor antagonists. Lancet, The, 2000, 355, 330-331.	13.7	45
222	The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. European Heart Journal, 2008, 30, 857-865.	2.2	45
223	EuroHeart score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary intervention. European Heart Journal, 2011, 32, 1398-1408.	2.2	45
224	Impact of Impaired Renal Function and Metabolic Syndrome on the Recurrence of Atrial Fibrillation after Catheter Ablation: A Long Term Followâ€Up. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 532-543.	1.2	45
225	Usefulness of transesophageal echocardiography in identifying small left ventricular apical thrombus. Journal of the American College of Cardiology, 1993, 21, 208-215.	2.8	44
226	Updated classification and management of pulmonary hypertension. Heart, 2010, 96, 552-559.	2.9	44
227	The Effect of Age on Outcomes of Coronary Artery Bypass Surgery Compared With Balloon Angioplasty or Bare-Metal Stent Implantation Among Patients With Multivessel Coronary Disease. Journal of the American College of Cardiology, 2012, 60, 2150-2157.	2.8	44
228	Current Results of Surgical Aortic Valve Replacement: Insights From the German Aortic Valve Registry. Annals of Thoracic Surgery, 2016, 101, 658-666.	1.3	44
229	Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-7.	1.7	44
230	Transcatheter closure of atrial septal defect and patent foramen ovale in adult patients using the Amplatzer occlusion device: No evidence for thrombus deposition with antiplatelet agents. Journal of the American Society of Echocardiography, 2002, 15, 1094-1098.	2.8	43
231	Withdrawal of Statins in Patients With Acute Coronary Syndromes. Circulation, 2003, 107, e27.	1.6	43
232	Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation 10, 10, 10, 10, 10, 10, 10, 10, 10, 10,	2.7	43
233	Journal, 2013, 165, 515-522. Transfemoral Aortic Valve Implantation of Edwards <scp>SAPIEN XT</scp> Without Predilatation Is Feasible. Clinical Cardiology, 2014, 37, 667-671.	1.8	43
234	Pre- and early in-hospital procedures in patients with acute coronary syndromes: first results of the "German chest pain unit registry― Clinical Research in Cardiology, 2012, 101, 983-991.	3.3	42

#	Article	IF	Citations
235	Comparison of outcomes using balloon-expandable versus self-expanding transcatheter prostheses according to the extent of aortic valve calcification. Clinical Research in Cardiology, 2017, 106, 995-1004.	3.3	42
236	Acute coronary syndromes: diagnosis. Lancet, The, 1999, 353, s10-s15.	13.7	41
237	Cryoballoon ablation of persistent atrial fibrillation: feasibility and safety of left atrial roof ablation with generation of conduction block in addition to antral pulmonary vein isolation. Europace, 2016, 19, euw146.	1.7	41
238	Ticagrelor or Prasugrel in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2020, 76, 2436-2446.	2.8	41
239	Asymptomatic recurrences of atrial fibrillation after pulmonary vein isolation. Europace, 2006, 8, 495-498.	1.7	40
240	NT-ProBNP Predicts Rhythm Stability After Cardioversion of Lone Atrial Fibrillation. Circulation Journal, 2008, 72, 921-925.	1.6	40
241	Release Kinetics of Copeptin in Patients Undergoing Transcoronary Ablation of Septal Hypertrophy. Clinical Chemistry, 2013, 59, 566-569.	3.2	40
242	Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of cardiac surgery associated acute kidney injury. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 392-399.	1.2	40
243	Criteria of the German Society of Cardiology for the establishment of chest pain units: update 2014. Clinical Research in Cardiology, 2015, 104, 918-928.	3.3	40
244	Patients at Intermediate Surgical Risk Undergoing Isolated Interventional or Surgical Aortic Valve Implantation for Severe Symptomatic Aortic Valve Stenosis. Circulation, 2018, 138, 2611-2623.	1.6	40
245	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2017, 52, 206-217.	1.4	39
246	1-Year Survival After TAVR of Patients With Low-Flow, Low-Gradient and High-Gradient Aortic Valve Stenosis in Matched Study Populations. JACC: Cardiovascular Interventions, 2019, 12, 752-763.	2.9	39
247	TAVI risk scoring using established versus new scoring systems: role of the new STS/ACC model. EuroIntervention, 2018, 13, 1520-1526.	3.2	39
248	Three-year follow-up of the ARTS-II# $\hat{a} \in \hat{s}$ sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. EuroIntervention, 2008, 3, 450-459.	3.2	39
249	Influence of Stent Length and Heparin Coating on Platelet Activation. Thrombosis Research, 1999, 94, 79-86.	1.7	38
250	Sympathoadrenergic overstimulation in Tako-Tsubo cardiomyopathy triggered by physical and emotional stress. International Journal of Cardiology, 2008, 130, 266-268.	1.7	38
251	Diagnostic and prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) in patients with chronic aortic regurgitation. International Journal of Cardiology, 2008, 127, 321-327.	1.7	38
252	Regression of cardiac hypertrophy by granulocyte colony-stimulating factor-stimulated interleukin- \hat{l}^2 synthesis. European Heart Journal, 2012, 33, 595-605.	2.2	38

#	Article	IF	CITATIONS
253	Release Kinetics of Cardiac Biomarkers in Patients Undergoing Transcoronary Ablation of Septal Hypertrophy. Clinical Chemistry, 2012, 58, 1049-1054.	3.2	38
254	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and AcuteACoronary Syndromes Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1905-1913.	2.9	38
255	Prospective randomized comparison of durability of bidirectional conduction block in the cavotricuspid isthmus in patients after ablation of common atrial flutter using cryothermy and radiofrequency energy: The CRYOTIP study. Heart Rhythm, 2009, 6, 1699-1705.	0.7	37
256	Detection of Relevant Coronary Artery Disease Using Dual-Source Computed Tomography in a High Probability Patient Series Comparison With Invasive Angiography. Circulation Journal, 2009, 73, 316-322.	1.6	37
257	Pexelizumab and Infarct Size in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Imaging, 2010, 3, 52-60.	5.3	37
258	Ischemia triggers BNP expression in the human myocardium independent from mechanical stress. International Journal of Cardiology, 2010, 143, 289-297.	1.7	37
259	Right ventricular adaptation to pulmonary pressure load in patients with chronic thromboembolic pulmonary hypertension before and after successful pulmonary endarterectomy - a cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 96.	3.3	37
260	Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension. Clinical Research in Cardiology, 2015, 104, 175-184.	3.3	37
261	In-hospital mortality in propensity-score matched low-risk patients undergoing routine isolated surgical or transfemoral transcatheter aortic valve replacement in 2014 in Germany. Clinical Research in Cardiology, 2017, 106, 610-617.	3.3	37
262	In vitro model to test the thrombogenicity of coronary stents. Thrombosis Research, 1994, 75, 581-590.	1.7	36
263	The golden hour of prehospital reperfusion with triple antiplatelet therapy: A sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy. American Heart Journal, 2010, 160, 1079-1084.	2.7	36
264	Plasma microRNA-21 for the early prediction of acute kidney injury in patients undergoing major cardiac surgery. Nephrology Dialysis Transplantation, 2016, 31, 760-766.	0.7	36
265	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors. JAMA Cardiology, 2017, 2, 127.	6.1	36
266	N-terminal pro–B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 639-646.	0.6	36
267	Diagnostic utility of new immunoassays for the cardiac markers cTnI, myoglobin and CK-MB mass. Clinical Biochemistry, 2005, 38, 1027-1030.	1.9	35
268	Usefulness of Atrial Fibrillation Burden as a Predictor for Success of Pulmonary Vein Isolation. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 1292-1301.	1.2	35
269	Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin. JACC: Cardiovascular Interventions, 2015, 8, 424-433.	2.9	35
270	Mechanisms involved in postconditioning protection of cardiomyocytes against acute reperfusion injury. Journal of Molecular and Cellular Cardiology, 2013, 58, 209-216.	1.9	34

#	Article	IF	Citations
271	Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: An APEX AMI substudy. International Journal of Cardiology, 2013, 168, 2127-2133.	1.7	34
272	CT Angiography for the Detection of CoronaryÂArtery StenosesÂin Patients Referred forÂCardiac Valve Surgery. JACC: Cardiovascular Imaging, 2016, 9, 1059-1070.	5.3	34
273	Enhanced coagulation activation in troponin T–positive unstable angina pectoris. American Heart Journal, 1998, 135, 281-286.	2.7	33
274	Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Heart, 2010, 96, 1815-1820.	2.9	33
275	Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of contrast-induced nephropathy after percutaneous coronary intervention. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 81-88.	1.2	32
276	New potential diagnostic biomarkers for pulmonary hypertension. European Respiratory Journal, 2015, 46, 1390-1396.	6.7	32
277	Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 250-258.	0.6	32
278	Implications of troponin testing in clinical medicine. Current Controlled Trials in Cardiovascular Medicine, 2001, 2, 75.	1.5	31
279	GuÃa de práctica clÃnica de la ESC para el manejo del sÃndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Revista Espanola De Cardiologia, 2012, 65, 173.e1-173.e55.	1.2	31
280	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions. Circulation, 2016, 134, 723-733.	1.6	31
281	Effect of Pre-Hospital Ticagrelor During the FirstÂ24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2016, 9, 646-656.	2.9	31
282	Prognostic Value of Undetectable hs Troponin T in Suspected Acute Coronary Syndrome. American Journal of Medicine, 2016, 129, 274-282.e2.	1.5	31
283	A non-contrast self-navigated 3-dimensional MR technique for aortic root and vascular access route assessment in the context of transcatheter aortic valve replacement: proof of concept. European Radiology, 2016, 26, 951-958.	4.5	31
284	Inhibition of Protein Prenylation of GTPases Alters Endothelial Barrier Function. International Journal of Molecular Sciences, 2020, 21, 2.	4.1	31
285	How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery. Clinical Research in Cardiology, 2009, 98, 8-15.	3.3	30
286	Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Archives of Cardiovascular Diseases, 2009, 102, 485-496.	1.6	30
287	Non-Invasive Approach for Evaluation of Pulmonary Hypertension Using Extracellular Vesicle-Associated Small Non-Coding RNA. Biomolecules, 2019, 9, 666.	4.0	30
288	Role of PI3K/Akt and MEK/ERK Signalling in cAMP/Epac-Mediated Endothelial Barrier Stabilisation. Frontiers in Physiology, 2019, 10, 1387.	2.8	30

#	Article	IF	CITATIONS
289	A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2005, 150, 401.e1-401.e7.	2.7	29
290	Temporary third-degree atrioventricular block in a case of apical ballooning syndrome. International Journal of Cardiology, 2006, 113, E33-E35.	1.7	29
291	Release pattern of N–terminal pro B–type natriuretic peptide (NT–proBNP) in acute coronary syndromes. Clinical Research in Cardiology, 2006, 95, 270-280.	3.3	29
292	Relation of N-Terminal Pro-B-Type Natriuretic Peptide to Symptoms, Severity, and Left Ventricular Remodeling in Patients With Organic Mitral Regurgitation. American Journal of Cardiology, 2009, 104, 559-564.	1.6	29
293	Prima-vista multi-vessel percutaneous coronary intervention in haemodynamically stable patients with acute coronary syndromes: Analysis of over 4.400 patients in the EHS-PCI registry. International Journal of Cardiology, 2013, 166, 596-600.	1.7	29
294	Cortisol awakening and stress response, personality and psychiatric profiles in patients with takotsubo cardiomyopathy. Heart, 2014, 100, 1786-1792.	2.9	29
295	Release kinetics of early ischaemic biomarkers in a clinical model of acute myocardial infarction. Heart, 2014, 100, 652-657.	2.9	29
296	Ischemia and reperfusion related myocardial inflammation: A network of cells and mediators targeting the cardiomyocyte. IUBMB Life, 2015, 67, 110-119.	3.4	29
297	Secondâ€generation cryoballoon ablation for treatment of persistent atrial fibrillation: Threeâ€year outcome and predictors of recurrence after a single procedure. Journal of Cardiovascular Electrophysiology, 2018, 29, 38-45.	1.7	29
298	Mechanisms of Stress (Takotsubo) Cardiomyopathy. Heart Failure Clinics, 2013, 9, 197-205.	2.1	28
299	Disease distribution and outcome in troponin-positive patients with or without revascularization in a chest pain unit: results of the German CPU-Registry. Clinical Research in Cardiology, 2014, 103, 29-40.	3.3	28
300	Analytical and diagnostic performance of troponin assays in patients suspicious for acute coronary syndromes. Clinical Biochemistry, 2000, 33, 359-368.	1.9	27
301	Acute Coronary Syndromes. Thrombosis Research, 2001, 103, S63-S69.	1.7	27
302	Radiation dose exposure in multislice computed tomography of the coronaries in comparison with conventional coronary angiography. International Journal of Cardiology, 2008, 124, 307-311.	1.7	27
303	13-year follow-up of the German angioplasty bypass surgery investigation. European Heart Journal, 2005, 26, 2148-2153.	2.2	26
304	Coronary interventions in the elderly. Heart, 2006, 92, 1167-1171.	2.9	26
305	2014 ESC/EACTS Guidelines on Myocardial Revascularization. Revista Espanola De Cardiologia (English) Tj ETQq1	1.0.78431 0.6	14 rgBT /Ov 26
306	Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. Journal of Thrombosis and Thrombolysis, 2015, 40, 317-322.	2.1	26

#	Article	IF	Citations
307	Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion. International Journal of Cardiology, 2015, 179, 90-94.	1.7	26
308	Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally?Sometimes earlier may not be betterBackground, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction. European Heart Journal, 2016, 37, 3316-3323.	2.2	26
309	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. Circulation, 2016, 133, 248-255.	1.6	26
310	Accuracy of device landing zone calcium volume measurement with contrast-enhanced multidetector computed tomography. International Journal of Cardiology, 2018, 263, 171-176.	1.7	26
311	Five-year outcome and predictors of success after second-generation cryoballoon ablation for treatment of symptomatic atrial fibrillation. International Journal of Cardiology, 2018, 266, 106-111.	1.7	26
312	Ticagrelor or Prasugrel in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation, 2020, 142, 2329-2337.	1.6	26
313	Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial). EuroIntervention, 2007, 3, 206-212.	3.2	26
314	Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry. American Heart Journal, 2006, 152, 1146-1152.	2.7	25
315	Implantation of sirolimus-eluting stents in saphenous vein grafts is associated with high clinical follow-up event rates compared with treatment of native vessels. Coronary Artery Disease, 2007, 18, 559-564.	0.7	25
316	Early Discharge After Primary Percutaneous Coronary Intervention: The Added Value of Nâ€Terminal Proâ€"Brain Natriuretic Peptide to the Zwolle Risk Score. Journal of the American Heart Association, 2014, 3, e001089.	3.7	25
317	Fate of Patients With Coronary Perforation Complicating Percutaneous Coronary Intervention (from) Tj ETQq1 1 Cardiology, 2015, 116, 1363-1367.	0.784314 1.6	
318	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding. Journal of the American College of Cardiology, 2016, 67, 596-598.	2.8	25
319	Transfemoral aortic valve implantation of Edwards SAPIEN 3 without predilatation. Catheterization and Cardiovascular Interventions, 2017, 89, E38-E43.	1.7	25
320	Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 200-206.	3.0	25
321	Risk stratifying acute coronary syndromes: Gradient of risk and benefit. American Heart Journal, 1999, 138, s6-s11.	2.7	24
322	Release pattern of cardiac biomarkers in left ventricular apical ballooning. International Journal of Cardiology, 2007, 115, 128-129.	1.7	24
323	The Study Of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): Design and rationale. American Heart Journal, 2012, 164, 646-653.e3.	2.7	24
324	Impact of Access Site on Bleeding andÂlschemic Events in Patients With Non–ST-Segment Elevation Myocardial Infarction Treated With Prasugrel. JACC: Cardiovascular Interventions, 2016, 9, 897-907.	2.9	24

#	Article	lF	CITATIONS
325	Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German–Austrian ABSORB RegIstRy (GABI-R). Cardiovascular Revascularization Medicine, 2016, 17, 34-37.	0.8	24
326	Baroreflex activation therapy. Journal of Cardiovascular Medicine, 2017, 18, 641-649.	1.5	24
327	Transcatheter Versus Rapid-Deployment Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 2642-2654.	2.9	24
328	Initial experience with a hydrophilic-coated guidewire for recanalization of chronic coronary occlusions. Catheterization and Cardiovascular Interventions, 2000, 49, 45-50.	1.7	23
329	Stem cells in myocardial infarction: from bench to bedside. Heart, 2009, 95, 508-514.	2.9	23
330	A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non–ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study. American Heart Journal, 2011, 161, 650-656.e1.	2.7	23
331	Relationship Between Palpography and Virtual Histology in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Imaging, 2012, 5, S19-S27.	5 . 3	23
332	Renal Sympathetic Denervation Does Not Aggravate Functional or Structural Renal Damage. Journal of the American College of Cardiology, 2013, 61, 479-480.	2.8	23
333	Learning Curve in Cryoballoon Ablation of Atrial Fibrillation. Circulation Journal, 2014, 78, 1612-1618.	1.6	23
334	Myocardial injury associated with transcatheter aortic valve implantation (TAVI). Clinical Research in Cardiology, 2016, 105, 379-387.	3.3	23
335	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. European Heart Journal, 2016, 37, 1122-1130.	2.2	23
336	A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives. International Journal of Cardiology, 2017, 227, 127-133.	1.7	23
337	Efficacy and Safety of TicagrelorÂMonotherapy in PatientsÂUndergoing Multivessel PCI. Journal of the American College of Cardiology, 2019, 74, 2015-2027.	2.8	23
338	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. American Journal of Cardiovascular Drugs, 2019, 19, 173-183.	2.2	23
339	Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroIntervention, 2007, 3, 371-380.	3.2	23
340	Short- and long-term health related quality-of-life and anginal status of the Arterial Revascularisation Therapies Study part II, ARTS-II; sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. EuroIntervention, 2010, 5, 962-967.	3.2	23
341	Myocardial Injury During Radiofrequency Catheter Ablation: Comparison of Focal and Linear Lesions. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 962-968.	1.2	22
342	Sirolimus eluting stent (Cypherâ,,¢) in patients with diabetes mellitus: results from the German Cypher Stent Registry. Clinical Research in Cardiology, 2008, 97, 105-109.	3.3	22

#	Article	IF	Citations
343	Antiplatelet therapy during surgery. Heart, 2010, 96, 986-991.	2.9	22
344	Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Journal of Thrombosis and Thrombolysis, 2012, 34, 106-113.	2.1	22
345	How to use C-reactive protein in acute coronary care. European Heart Journal, 2013, 34, 3687-3690.	2.2	22
346	Mitral valve leaflet repair with the new PASCAL system: early real-world data from a German multicentre experience. Clinical Research in Cardiology, 2020, 109, 549-559.	3.3	22
347	Purinergic Regulation of Endothelial Barrier Function. International Journal of Molecular Sciences, 2021, 22, 1207.	4.1	22
348	Diagnostic value of the 16-detector row multislice spiral computed tomography for the detection of coronary artery stenosis in comparison to invasive coronary angiography. Clinical Cardiology, 2007, 30, 118-123.	1.8	21
349	Image quality on dual-source computed-tomographic coronary angiography. European Radiology, 2008, 18, 1857-1862.	4.5	21
350	Atrial septal defects type II: noninvasive evaluation of patients before implantation of an Amplatzer Septal Occluder and on follow-up by magnetic resonance imaging compared with TEE and invasive measurement. European Radiology, 2008, 18, 2406-2413.	4.5	21
351	Predictors and outcome of grade 3 ischemia in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Journal of Electrocardiology, 2011, 44, 516-522.	0.9	21
352	Self-referral to chest pain units: results of the German CPU-registry. European Heart Journal: Acute Cardiovascular Care, 2012, 1, 312-319.	1.0	21
353	The effect of preâ€hospital glycoprotein Ilb–Illa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI. Catheterization and Cardiovascular Interventions, 2012, 79, 956-964.	1.7	21
354	Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis. International Journal of Cardiovascular Imaging, 2012, 28, 695-703.	1.5	21
355	Mobile left ventricular thrombus in left ventricular dysfunction: case report and review of literature. Clinical Research in Cardiology, 2013, 102, 479-484.	3.3	21
356	Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. Clinical Research in Cardiology, 2015, 104, 1064-1071.	3.3	21
357	Prognostic value of body mass index and body surface area on clinical outcomes after transcatheter aortic valve implantation. Clinical Research in Cardiology, 2016, 105, 1042-1048.	3.3	21
358	A multicenter postâ€marketing evaluation of the Elixir DESolve [®] Novolimusâ€eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. Catheterization and Cardiovascular Interventions, 2018, 92, 1021-1027.	1.7	21
359	Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. Clinical Research in Cardiology, 2018, 107, 49-59.	3.3	21
360	Ice or fire? Comparison of secondâ€generation cryoballoon ablation and radiofrequency ablation in patients with symptomatic persistent atrial fibrillation and an enlarged left atrium. Journal of Cardiovascular Electrophysiology, 2018, 29, 375-384.	1.7	21

#	Article	IF	CITATIONS
361	Multicentre cross-sectional observational registry to monitor the safety of early discharge after rule-out of acute myocardial infarction by copeptin and troponin: the Pro-Core registry. BMJ Open, 2019, 9, e028311.	1.9	21
362	Silicon carbide-coated stents in patients with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2003, 60, 375-381.	1.7	20
363	Anti-Integrin Therapy. Annual Review of Medicine, 2003, 54, 425-435.	12.2	20
364	Value of Gadolinium-Enhanced Magnetic Resonance Imaging in Patients with Tako-Tsubo-Like Left Ventricular Dysfunction. Journal of Cardiovascular Magnetic Resonance, 2006, 8, 367-372.	3.3	20
365	Does the Integration of Personalized Ultrasound Change Patient Management in Critical Care Medicine? Observational Trials. Emergency Medicine International, 2013, 2013, 1-8.	0.8	20
366	Role of the Phosphatase PTEN in Early Vascular Remodeling. PLoS ONE, 2013, 8, e55445.	2.5	20
367	Manual versus automatic detection of aortic annulus plane in a computed tomography scan for transcatheter aortic valve implantation screening. European Journal of Cardio-thoracic Surgery, 2014, 46, 207-212.	1.4	20
368	Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H547-H556.	3.2	20
369	Impact of Arterial Access Site on Outcomes After Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e002049.	3.9	20
370	A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial. American Heart Journal, 2016, 179, 69-76.	2.7	20
371	N-terminal fragment of cardiac myosin binding protein-C triggers pro-inflammatory responses in vitro. Journal of Molecular and Cellular Cardiology, 2016, 99, 47-56.	1.9	20
372	Treatment of In-Stent Coronary Restenosis by Excimer Laser Angioplasty. American Journal of Cardiology, 1997, 80, 1424-1428.	1.6	19
373	Membrane-covered stents: A new treatment strategy for saphenous vein graft lesions. Catheterization and Cardiovascular Interventions, 2001, 53, 1-4.	1.7	19
374	Cardiac Angiosarcoma Diagnosed and Characterized by Cardiac Magnetic Resonance Imaging. Cardiology in Review, 2006, 14, 101-103.	1.4	19
375	The value of magnetic resonance imaging for the diagnosis of arrhythmogenic right ventricular cardiomyopathy. European Radiology, 2006, 16, 560-568.	4.5	19
376	Sirolimus-eluting stent treatment for unprotected versus protected left main coronary artery disease in widespread clinical routine: 6-month and 3-year clinical follow-up results from the prospective multicentre German Cypher Registry. Heart, 2007, 93, 1251-1255.	2.9	19
377	Prognostic Value of the Modified American College of Cardiology/American Heart Association Lesion Morphology Classification for Clinical Outcome After Sirolimus-Eluting Stent Placement (Results of) Tj ETQq1 1 477-482.	0.784314 1.6	rgBT /Overlo
378	Cognitive decline and ischemic microlesions after coronary catheterization. A comparison to coronary artery bypass grafting. American Heart Journal, 2011, 162, 756-763.	2.7	19

#	Article	IF	Citations
379	A novel mutation in the cardiac ryanodine receptor gene (RyR2) in a patient with an unequivocal LQTS. International Journal of Cardiology, 2011, 146, 249-250.	1.7	19
380	Endogenous stress response in Tako-Tsubo cardiomyopathy and acute myocardial infarction. European Journal of Clinical Investigation, 2011, 41, 964-970.	3.4	19
381	The German CPU Registry: Comparison of troponin positive to troponin negative patients. International Journal of Cardiology, 2013, 168, 1651-1653.	1.7	19
382	Brain-Derived Neurotrophic Factor as aÂMarker for Immediate Assessment of the SuccessÂof Renal Sympathetic Denervation. Journal of the American College of Cardiology, 2015, 65, 1151-1153.	2.8	19
383	The German CPU Registry: Dyspnea independently predicts negative short-term outcome in patients admitted to German Chest Pain Units. International Journal of Cardiology, 2015, 181, 88-95.	1.7	19
384	Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction. Heart, 2017, 103, 1515-1520.	2.9	19
385	Transcatheter aortic valve implantation in Germany. Clinical Research in Cardiology, 2018, 107, 81-87.	3.3	19
386	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. International Journal of Cardiology, 2019, 286, 43-50.	1.7	19
387	Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension. Biomarkers, 2020, 25, 578-586.	1.9	19
388	Acute Success and Persistence of Bidirectional Conduction Block in the Cavotricuspid Isthmus One Month Post Cryocatheter Ablation of Common Atrial Flutter. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 146-152.	1.2	18
389	Electrical storm in a patient with arrhythmogenic right ventricular cardiomyopathy and SCN5A mutation. Europace, 2008, 10, 884-887.	1.7	18
390	Coronary Stenting with the Sirolimusâ€Eluting Stent in Clinical Practice: Final Results from the Prospective Multicenter <i>German Cypher Stent Registry</i> 2010, 23, 18-25.	1.2	18
391	Documento de consenso de expertos. Tercera definición universal del infarto de miocardio. Revista Espanola De Cardiologia, 2013, 66, 132.e1-132.e15.	1.2	18
392	Blood pressure variability after catheter-based renal sympathetic denervation in patients with resistant hypertension. Journal of Hypertension, 2015, 33, 2512-2518.	0.5	18
393	Comparison of quantitative stenosis characteristics at routine coronary computed tomography angiography with invasive fractional flow reserve for assessing lesion-specific ischemia. Journal of Cardiovascular Computed Tomography, 2015, 9, 546-552.	1.3	18
394	Identification of acute myocardial infarction in patients with atrial fibrillation and chest pain with a contemporary sensitive troponin I assay. BMC Medicine, 2015, 13, 169.	5.5	18
395	Predictors and outcome of conversion to cardiac surgery during transcatheter aortic valve implantation. European Journal of Cardio-thoracic Surgery, 2018, 54, 267-272.	1.4	18
396	PLAAF score as a novel predictor of long-term outcome after second-generation cryoballoon pulmonary vein isolation. Europace, 2018, 20, f436-f443.	1.7	18

#	Article	IF	CITATIONS
397	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). BMJ Open, 2019, 9, e026053.	1.9	18
398	High prevalence of vitamin D insufficiency in professional handball athletes. Physician and Sportsmedicine, 2019, 47, 71-77.	2.1	18
399	Transvascular transcatheter aortic valve implantation in 2017. Clinical Research in Cardiology, 2020, 109, 303-314.	3.3	18
400	Feasibility of Coronary Access in Patients With Acute Coronary Syndrome and Previous TAVR. JACC: Cardiovascular Interventions, 2021, 14, 1578-1590.	2.9	18
401	Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Preâ€Specified Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2021, 10, e015560.	3.7	18
402	Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. EuroIntervention, 2017, 13, 69-77.	3.2	18
403	Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. EuroIntervention, 2020, 16, 627-633.	3.2	18
404	Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: Insights from ARTS I and ARTS II. EuroIntervention, 2009, 4, 492-501.	3.2	18
405	B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide - Diagnostic role in stable coronary artery disease. Experimental and Clinical Cardiology, 2006, 11, 99-101.	1.3	18
406	Angiographic analysis of immediate and long-term results of PTCR vs. PTCA in complex lesions (COBRA) Tj ETQqC	0 0 rgBT 1.7	/Oyerlock 10
407	Apical regional wall motion abnormalities reminiscent to Tako-Tsubo cardiomyopathy following consumption of psychoactive fungi. International Journal of Cardiology, 2009, 134, e39-e41.	1.7	17
408	The Swedish paradox: or is there really no gender difference in acute coronary syndromes?. European Heart Journal, 2011, 32, 3070-3072.	2.2	17
409	Multi-detector computed tomography is equivalent to trans-oesophageal echocardiography for the assessment of the aortic annulus before transcatheter aortic valve implantation. European Radiology, 2012, 22, 2662-2669.	4.5	17
410	Venn Diagrams in Cardiovascular Disease: The Heart Team Concept. Annals of Thoracic Surgery, 2013, 95, 389-391.	1.3	17
411	Molecular basis of disturbed extracellular matrix homeostasis in stress cardiomyopathy. International Journal of Cardiology, 2013, 168, 1685-1688.	1.7	17
412	Impact of the learning curve on procedural results and acute outcome after percutaneous coronary interventions with everolimus-eluting bioresorbable scaffolds in an all-comers population. Cardiovascular Revascularization Medicine, 2015, 16, 455-460.	0.8	17
413	Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non–ST-Elevation Myocardial Infarction (ACCOAST) study. American Heart Journal, 2015, 170, 1025-1032,e2.	2.7	17
414	Endocarditis after interventional repair of the mitral valve: Review of a dilemma. Cardiovascular Revascularization Medicine, 2017, 18, 141-144.	0.8	17

#	Article	IF	CITATIONS
415	Transfemoral aortic valve implantation using a self-expanding transcatheter heart valve without pre-dilation. International Journal of Cardiology, 2017, 243, 156-160.	1.7	17
416	Second-generation cryoballoon ablation as a first-line treatment of symptomatic atrial fibrillation: Two-year outcome and predictors of recurrence after a single procedure. International Journal of Cardiology, 2018, 259, 76-81.	1.7	17
417	Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 208-217.	1.0	17
418	Prognostic Impact of Underweight (Body Mass Index <20 kg/m2) in Patients With Severe Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation or Surgical Aortic Valve Replacement (from the German Aortic Valve Registry [GARY]). American Journal of Cardiology, 2020, 129, 79-86.	1.6	17
419	Three-year clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularisation Therapies Study, part II (ARTS II). EuroIntervention, 2009, 5, 190-196.	3.2	17
420	Effects of lipoprotein(a) on lysis of whole blood thrombi from healthy volunteers. Thrombosis Research, 1993, 69, 479-487.	1.7	16
421	Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass. American Journal of Cardiology, 2003, 91, 346-347.	1.6	16
422	How to revascularize patients with diabetes mellitus—. Clinical Research in Cardiology, 2006, 95, 195-203.	3.3	16
423	Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology: reply. European Heart Journal, 2007, 29, 278-279.	2.2	16
424	Severe mitral regurgitation in Tako-Tsubo cardiomyopathy. International Journal of Cardiology, 2009, 132, e77-e79.	1.7	16
425	Pulmonary Vein Antrum Isolation and Terminal Part of the P Wave. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 784-789.	1.2	16
426	A Prospective, Single-Blind, Multicenter, Dose Escalation Study of Intracoronary iNOS Lipoplex (CAR-MP583) Gene Therapy for the Prevention of Restenosis in Patients with de novo or Restenotic Coronary Artery Lesion (REGENT I Extension). Human Gene Therapy, 2011, 22, 951-958.	2.7	16
427	The effect of internal thoracic artery grafts on long-term clinical outcomes after coronary bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 829-835.	0.8	16
428	Direct admission versus transfer of AMI patients for primary PCI. Clinical Research in Cardiology, 2011, 100, 217-225.	3.3	16
429	Venn diagrams in cardiovascular disease: the Heart Team concept. European Heart Journal, 2014, 35, 66-68.	2.2	16
430	German Heart Report 2013. Clinical Research in Cardiology, 2015, 104, 112-123.	3.3	16
431	High-sensitivity cardiac troponin T and copeptin assays to improve diagnostic accuracy of exercise stress test in patients with suspected coronary artery disease. European Journal of Preventive Cardiology, 2015, 22, 684-692.	1.8	16
432	Hemodynamic phenotyping based on exercise catheterization predicts outcome in patients with heart failure and reduced ejection fraction. Journal of Heart and Lung Transplantation, 2017, 36, 880-889.	0.6	16

#	Article	IF	Citations
433	Development of renal function during staged balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 268-275.	1.2	16
434	Outcome of patients with heart failure after transcatheter aortic valve implantation. PLoS ONE, 2019, 14, e0225473.	2.5	16
435	Clinical relevance of ticagrelor monotherapy following $1\hat{a} \in \mathbb{R}$ month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, 100-111.	1.7	16
436	Safety and effectiveness of coronary intravascular lithotripsy in eccentric calcified coronary lesions: a patient-level pooled analysis from the Disrupt CAD I and CAD II Studies. Clinical Research in Cardiology, 2021, 110, 228-236.	3.3	16
437	Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention, 2018, 13, e1841-e1849.	3.2	16
438	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. EuroIntervention, 2019, 15, e1090-e1098.	3.2	16
439	Residual Platelet Function Under Acetylsalicylic Acid and the Risk of Restenosis After Coronary Angioplasty. Journal of Cardiovascular Pharmacology, 1992, 19, 190-193.	1.9	15
440	Antibodies to chlamydial lipopolysaccharides in unstable angina pectoris. American Journal of Cardiology, 2001, 87, 1150-1153.	1.6	15
441	Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes. Thrombosis Research, 2007, 120, 811-814.	1.7	15
442	Sirolimus-Eluting Stent Treatment at High-Volume Centers Confers Lower Mortality at 6-Month Follow-Up. Circulation, 2009, 120, 600-606.	1.6	15
443	Bone marrow-derived cells contribute to cell turnover in aging murine hearts. International Journal of Molecular Medicine, 2012, 30, 283-287.	4.0	15
444	Cardiogoniometry as a diagnostic tool in patients with acute coronary syndromes: results of the CGM@ACS trial. Clinical Research in Cardiology, 2012, 101, 727-736.	3.3	15
445	Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: Role of P2Y1 and P2Y12 receptors. Thrombosis Research, 2013, 132, 548-557.	1.7	15
446	Patient-specific predictors of image noise in coronary CT angiography. Journal of Cardiovascular Computed Tomography, 2013, 7, 39-45.	1.3	15
447	The Impact of Left Atrial Surface Area and the Second Generation Cryoballoon on Clinical Outcome of Atrial Fibrillation Cryoablation. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 815-824.	1.2	15
448	Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart, 2015, 101, 1219-1224.	2.9	15
449	Influence of Renal Sympathetic Denervation on Cardiac Extracellular Matrix Turnover and Cardiac Fibrosis. American Journal of Hypertension, 2015, 28, 1285-1292.	2.0	15
450	Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization. Journal of the American College of Cardiology, 2016, 67, 1289-1297.	2.8	15

#	Article	IF	Citations
451	Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials. American Heart Journal, 2017, 194, 73-82.	2.7	15
452	Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction. Heart, 2018, 104, 1843-1849.	2.9	15
453	Dynamics of high-sensitivity cardiac troponin T during therapy with balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. PLoS ONE, 2018, 13, e0204683.	2.5	15
454	Left atrial roof ablation in patients with persistent atrial fibrillation using the second-generation cryoballoon: benefit or wasted time?. Clinical Research in Cardiology, 2020, 109, 714-724.	3.3	15
455	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e009177.	3.9	15
456	Impact of Predilatation Prior to Transcatheter Aortic Valve Implantation With the Self-Expanding Acurate neo Device (from the Multicenter NEOPRO Registry). American Journal of Cardiology, 2020, 125, 1369-1377.	1.6	15
457	GARYâ€"The Largest Registry of Aortic Stenosis Treatment Worldwide. European Heart Journal, 2020, 41, 733-735.	2.2	15
458	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. European Respiratory Journal, 2021, 57, 1901192.	6.7	15
459	Sham Surgery and Inter-Individual Heterogeneity Are Major Determinants of Monocyte Subset Kinetics in a Mouse Model of Myocardial Infarction. PLoS ONE, 2014, 9, e98456.	2.5	15
460	Everolimus-eluting bioresorbable scaffolds in patients with coronary artery disease: results from the German-Austrian ABSORB RegIstRy (GABI-R). EuroIntervention, 2017, 13, 1311-1318.	3.2	15
461	Higher efficacy of pre-hospital tirofiban with longer pre-treatment time to primary PCI: protection for the negative impact of time delay. EuroIntervention, 2011, 7, 442-448.	3.2	15
462	Incidence and predictors of target vessel revascularization after sirolimus-eluting stent treatment for proximal left anterior descending artery stenoses among 2274 patients fromthe prospectivemulticenter German Cypher Stent Registry. Clinical Research in Cardiology, 2007, 96, 279-284.	3.3	14
463	Tako-Tsubo cardiomyopathy: NT-proBNP as a reliable parameter of a favourable prognosis?. International Journal of Cardiology, 2008, 124, 237-238.	1.7	14
464	Elevated serum levels of neuropeptide Y in stress cardiomyopathy. International Journal of Cardiology, 2011, 147, 155-157.	1.7	14
465	Midregional Proadrenomedullin Improves Risk Stratification beyond Surgical Risk Scores in Patients Undergoing Transcatheter Aortic Valve Replacement. PLoS ONE, 2015, 10, e0143761.	2.5	14
466	Primary endpoint results of the OMEGA Study: One-year clinical outcomes after implantation of a novel platinum chromium bare metal stent. Cardiovascular Revascularization Medicine, 2015, 16, 65-69.	0.8	14
467	Cyclic changes in area- and perimeter-derived effective dimensions of the aortic annulus measured with multislice computed tomography and comparison with metric intraoperative sizing. Clinical Research in Cardiology, 2016, 105, 622-629.	3.3	14
468	Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 659-665.	1.0	14

#	Article	IF	CITATIONS
469	Interval From Initiation of Prasugrel toÂCoronary Angiography in PatientsÂWith Non–ST-Segment ElevationÂMyocardialÂInfarction. Journal of the American College of Cardiology, 2019, 73, 906-914.	2.8	14
470	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovascular Diabetology, 2020, 19, 179.	6.8	14
471	Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events. Thrombosis and Haemostasis, 2020, 120, 1087-1095.	3.4	14
472	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology, 2020, 109, 930-943.	3.3	14
473	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. Clinical Research in Cardiology, 2020. 109. 1125-1139.	3.3	14
474	Cardiac Troponin I: A Valuable Biomarker Indicating the Cardiac Involvement in Fabry Disease. PLoS ONE, 2016, 11, e0157640.	2.5	14
475	Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. American Heart Journal, 1995, 130, 711-716.	2.7	13
476	Multicenter evaluation of the Strecker tantalum stent for acute coronary occlusion after angioplasty. American Heart Journal, 1995, 129, 423-429.	2.7	13
477	Acute and long-term results of PVI at antrum using a novel high-density mapping catheter without help of 3D electro-anatomic mapping in patients with paroxysmal and chronic atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2010, 27, 101-108.	1.3	13
478	Major depression as a potential trigger for Tako Tsubo cardiomyopathy. International Journal of Cardiology, 2010, 140, e40-e42.	1.7	13
479	Maladaptive hypertrophy after acute myocardial infarction positive effect of bone marrow-derived stem cell therapy on regional remodeling measured by cardiac MRI. Clinical Research in Cardiology, 2011, 100, 983-992.	3.3	13
480	Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: Insights from the Euro heart survey PCI registry. Catheterization and Cardiovascular Interventions, 2011, 78, 702-709.	1.7	13
481	High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. Heart, 2011, 97, 626-631.	2.9	13
482	Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): An international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary intervention. American Heart Journal, 2013, 166, 960-967.e6.	2.7	13
483	Electrophysiological Studies in Patients with Pulmonary Hypertension: A Retrospective Investigation. BioMed Research International, 2014, 2014, 1-6.	1.9	13
484	Pulmonary vascular remodeling before and after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: a cardiac magnetic resonance study. International Journal of Cardiovascular Imaging, 2015, 31, 613-619.	1.5	13
485	Safety and feasibility of percutaneous skin closure using purseâ€string suture compared with compression bandage after pulmonary vein isolation. Journal of Cardiovascular Electrophysiology, 2017, 28, 1048-1057.	1.7	13
486	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e005635.	3.9	13

#	Article	IF	Citations
487	An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany. BMC Cardiovascular Disorders, 2018, 18, 163.	1.7	13
488	The DEDICATE Trial. European Heart Journal, 2019, 40, 331-333.	2.2	13
489	Clinical outcome and left atrial function after left atrial roof ablation using the cryoballoon technique in patients with symptomatic persistent atrial fibrillation. International Journal of Cardiology, 2019, 292, 112-118.	1.7	13
490	Multicentre propensity-matched comparison of transcatheter aortic valve implantation using the ACURATE TA/neo self-expanding versus the SAPIEN 3 balloon-expandable prosthesis. EuroIntervention, 2019, 15, 884-891.	3.2	13
491	Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial. EuroIntervention, 2010, 6, 336-342.	3.2	13
492	Delayed Contrast-Enhanced Magnetic Resonance Imaging For the Detection of Autoimmune Myocarditis and Long-term Follow-Up. Journal of Cardiovascular Magnetic Resonance, 2005, 7, 521-523.	3 . 3	12
493	Cardiac metastasis of a renal cell adenocarcinoma investigated by cardiac magnetic resonance imaging. Clinical Research in Cardiology, 2006, 95, 492-495.	3.3	12
494	German stereotaxis-guided percutaneous coronary intervention study group: first multicenter real world experience. Clinical Research in Cardiology, 2009, 98, 541-547.	3 . 3	12
495	Cobalt–chrome MULTI-LINK VISIONâ,,¢-stent implantation in diabetics and complex lesions: results from the DaVinci-Registry. Clinical Research in Cardiology, 2009, 98, 731-737.	3.3	12
496	Limitaciones de la determinación de los niveles de los biomarcadores séricos durante el aislamiento de venas pulmonares. Revista Espanola De Cardiologia, 2011, 64, 127-132.	1.2	12
497	Ultrasound guided percutaneous thrombin injection in a radial artery pseudoaneurysm following percutaneous coronary intervention. Clinical Research in Cardiology, 2014, 103, 1022-1024.	3 . 3	12
498	Release kinetics of N-terminal pro-B-type natriuretic peptide in a clinical model of acute myocardial infarction. Clinica Chimica Acta, 2014, 429, 34-37.	1.1	12
499	Gender differences in therapeutic recommendation after diagnostic coronary angiography: insights from the Coronary Angiography and PCI Registry of the German Society of Cardiology. Clinical Research in Cardiology, 2015, 104, 507-517.	3.3	12
500	Angiographic Findings and Revascularization Success in Patients With Acute Myocardial Infarction and Previous Coronary Bypass Grafting. American Journal of Cardiology, 2016, 118, 473-476.	1.6	12
501	Everolimus-Versus Novolimus-Eluting Bioresorbable Scaffolds for the TreatmentÂof Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 477-485.	2.9	12
502	Applicability of a Novel Formula (<i>Bogossian formula</i>) for Evaluation of the QTâ€Interval in Heart Failure and Left Bundle Branch Block Due to Right Ventricular Pacing. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 409-416.	1.2	12
503	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION) Tj ETQq1 1 0.7843	14 rgBT /(1.8	Overlock 10 T
504	High adherence to therapy and low cardiac mortality and morbidity in patients after acute coronary syndrome systematically managed by office-based cardiologists in Germany: 1-year outcomes of the ProAcor Study. Vascular Health and Risk Management, 2017, Volume 13, 127-137.	2.3	12

#	Article	IF	CITATIONS
505	Impact of preprocedural TIMI flow on clinical outcome in lowâ€risk patients with STâ€elevation myocardial infarction: Results from the ATLANTIC study. Catheterization and Cardiovascular Interventions, 2020, 95, 494-500.	1.7	12
506	Challenges of recognizing bicuspid aortic valve in elderly patients undergoing TAVR. International Journal of Cardiovascular Imaging, 2020, 36, 251-256.	1.5	12
507	Effectiveness and Safety of the ACURATEÂNeoÂProsthesis in 1,000 Patients With Aortic Stenosis. American Journal of Cardiology, 2020, 131, 12-16.	1.6	12
508	Aortic valve replacement in Germany in 2019. Clinical Research in Cardiology, 2021, 110, 460-465.	3.3	12
509	Determinants of paravalvular leakage following transcatheter aortic valve replacement in patients with bicuspid and tricuspid aortic stenosis. European Heart Journal Cardiovascular Imaging, 2021, , .	1.2	12
510	Implantation of a novolimus-eluting bioresorbable scaffold with a strut thickness of 100 $\hat{A}\mu m$ showing evidence of self-correction. EuroIntervention, 2015, 11, 204-204.	3.2	12
511	Critical Role of Dose in Protection by Propranolol Against Ventricular Fibrillation in a Pig Model of Acute Myocardial Ischemia. Journal of Cardiovascular Pharmacology, 1989, 13, 192-197.	1.9	11
512	Multicenter Pilot Study of a Serpentine Balloon-Expandable Stent (beStentTM): Acute Angiographic and Clinical Results. Journal of Interventional Cardiology, 1997, 10, 277-286.	1.2	11
513	Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry. Clinical Research in Cardiology, 2008, 97, 432-440.	3.3	11
514	Percutaneous circulatory support in a patient with cardiac arrest due to acute pulmonary embolism. Clinical Research in Cardiology, 2012, 101, 1017-1020.	3.3	11
515	The Future of TAVI. European Heart Journal, 2017, 38, 2704-2707.	2.2	11
516	Effect of ticagrelor on endothelial calcium signalling and barrier function. Thrombosis and Haemostasis, 2017, 117, 371-381.	3.4	11
517	Specific biomarkers of myocardial inflammation and remodeling processes as predictors of mortality in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 481-487.	1.8	11
518	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. Thrombosis and Haemostasis, 2020, 120, 065-074.	3.4	11
519	Copeptin combined with either non-high sensitivity or high sensitivity cardiac troponin for instant rule-out of suspected non-ST segment elevation myocardial infarction. Biomarkers, 2020, 25, 649-658.	1.9	11
520	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006660.	2.2	11
521	SPARCL1 as a biomarker of maladaptive right ventricular remodelling in pulmonary hypertension. Biomarkers, 2020, 25, 290-295.	1.9	11
522	Transcatheter or surgical aortic valve implantation in chronic dialysis patients: a German Aortic Valve Registry analysis. Clinical Research in Cardiology, 2021, 110, 357-367.	3.3	11

#	Article	IF	CITATIONS
523	Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology—Cardiovascular Round Table. Cardiovascular Research, 2021, 117, 1248-1256.	3.8	11
524	Effects of BPA on right ventricular mechanical dysfunction in patients with inoperable CTEPH – A cardiac magnetic resonance study. European Journal of Radiology, 2022, 147, 110111.	2.6	11
525	Complications of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: Impact on the outcome. Journal of Heart and Lung Transplantation, 2022, 41, 1086-1094.	0.6	11
526	Protective effects on isolated hearts with developing infarction: Slow channel blockade by diltiazem versus beta-adrenoceptor antagonism by metoprolol. American Journal of Cardiology, 1982, 50, 857-863.	1.6	10
527	Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. American Heart Journal, 1998, 135, s56-s66.	2.7	10
528	Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry. Clinical Research in Cardiology, 2012, 101, 709-716.	3.3	10
529	Interobserver agreement for the detection of atherosclerotic plaque in coronary CT angiography: comparison of two low-dose image acquisition protocols with standard retrospectively ECG-gated reconstruction. European Radiology, 2012, 22, 1529-1536.	4.5	10
530	Ipsilateral Circumferential Radiofrequency Ablation of Atrial Fibrillation With Irrigated Tip Catheter. Circulation Journal, 2013, 77, 2280-2287.	1.6	10
531	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	10
532	Safety of the Wearable Cardioverter Defibrillator (WCD) in Patients with Implanted Pacemakers. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 271-277.	1.2	10
533	Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100. International Journal of Cardiology, 2017, 246, 74-79.	1.7	10
534	Release kinetics of high-sensitivity cardiac troponins I and T and troponin T upstream open reading frame peptide (TnTuORF) in clinically induced acute myocardial infarction. Biomarkers, 2017, 22, 304-310.	1.9	10
535	Duration of ischemia and treatment effects of pre-versus in-hospital ticagrelor in patients with ST-segment elevation myocardial infarction: Insights from the ATLANTIC study. American Heart Journal, 2018, 196, 56-64.	2.7	10
536	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. International Journal of Cardiology, 2018, 270, 96-101.	1.7	10
537	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007342.	3.9	10
538	Lower mortality in an all-comers aortic stenosis population treated with TAVI in comparison to SAVR. Clinical Research in Cardiology, 2020, 109, 611-615.	3.3	10
539	Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, , .	3.0	10
540	Comparison of Investigator-Reported and Clinical Event Committee–Adjudicated Outcome Events in GLASSY. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e006581.	2.2	10

#	Article	IF	CITATIONS
541	Percutaneous Coronary Intervention in Transcatheter Aortic Valve Implantation Patients: Overview and Practical Management. Frontiers in Cardiovascular Medicine, 2021, 8, 653768.	2.4	10
542	Impact of chronic kidney disease in 29 893 patients undergoing transcatheter or surgical aortic valve replacement from the German Aortic Valve Registry. European Journal of Cardio-thoracic Surgery, 2021, 59, 532-544.	1.4	10
543	Predictors of permanent pacemaker implantation after ACURATE <i>neo </i> transcatheter heart valve implantation. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 410-415.	1.2	10
544	Left ventricular function determines the survival benefit for women over men after transcatheter aortic valve implantation (TAVI). EuroIntervention, 2017, 13, 467-474.	3.2	10
545	Predictors of recurrent stroke after percutaneous closure of patent foramen ovale. EuroIntervention, 2014, 9, 1418-1422.	3.2	10
546	Predictors of early and late left atrial tachycardia and left atrial flutter after catheter ablation of atrial fibrillation: Long-term follow-up. Cardiology Journal, 2015, 22, 557-566.	1.2	10
547	Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes—observations from the TARGET trial. American Journal of Cardiology, 2003, 92, 125-129.	1.6	9
548	Symptomatic atrial fibrillation as the first symptom of a giant left atrial appendage aneurysm. Clinical Research in Cardiology, 2006, 95, 614-616.	3.3	9
549	Novel biomarkersthe long march from bench to bedside. European Heart Journal, 2008, 29, 1079-1081.	2.2	9
550	Calcium and C-Reactive Protein. Journal of the American College of Cardiology, 2011, 57, 1465-1467.	2.8	9
551	Limitations of Biomarkers Serum Levels During Pulmonary Vein Isolation. Revista Espanola De Cardiologia (English Ed), 2011, 64, 127-132.	0.6	9
552	Rescue valve-in-valve implantations in second generation transapical transcatheter aortic valve prostheses. Clinical Research in Cardiology, 2013, 102, 241-243.	3.3	9
553	Ivabradine therapy to unmask heart rate-independent effects of β-blockers on pulse wave reflections. Clinical Research in Cardiology, 2014, 103, 487-494.	3.3	9
554	Identification of Periprocedural Myocardial Infarction Using a High-Sensitivity Troponin I Assay in Patients Who Underwent Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 1180-1186.	1.6	9
555	Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 2017, 117, 1093-1100.	3.4	9
556	Elite athletes as research model: vitamin D insufficiency associates with elevated central blood pressure in professional handball athletes. European Journal of Applied Physiology, 2019, 119, 2265-2274.	2.5	9
557	High-Content Immunophenotyping and Hierarchical Clustering Reveal Sources of Heterogeneity and New Surface Markers of Human Blood Monocyte Subsets. Thrombosis and Haemostasis, 2020, 120, 141-155.	3.4	9
558	<scp>QTc</scp> interval evaluation in patients with right bundle branch block or bifascicular blocks. Clinical Cardiology, 2020, 43, 957-962.	1.8	9

#	Article	IF	CITATIONS
559	Exercise right heart catheterization before and after balloon pulmonary angioplasty in inoperable patients with chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-9.	1.7	9
560	Surgical aortic valve replacement in patients aged 50–69 years—insights from the German Aortic Valve Registry (GARY). European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	9
561	Membrane-covered stents for the treatment of aortocoronary vein graft disease. Catheterization and Cardiovascular Interventions, 2000, 50, 83-88.	1.7	8
562	Outcome in the elderly undergoing percutaneous coronary intervention with sirolimus-eluting stents: Results from the prospective multicenter German Cypher Stent Registry. American Heart Journal, 2007, 154, 682-687.	2.7	8
563	Sirolimus-eluting stents in the treatment of chronic total coronary occlusions. Clinical Research in Cardiology, 2008, 97, 253-259.	3.3	8
564	Genetic polymorphism of the type A human natriuretic peptide receptor (NPRâ€A) gene contributes to the interindividual variability in the BNP system. European Journal of Heart Failure, 2008, 10, 482-489.	7.1	8
565	Multivessel percutaneous coronary intervention in patients with stable angina: a common approach? Lessons learned from the EHS PCI registry. Heart and Vessels, 2012, 27, 453-459.	1.2	8
566	Venn diagrams in cardiovascular disease: the Heart Team concept. European Journal of Cardio-thoracic Surgery, 2013, 43, 255-257.	1.4	8
567	Implantation of everolimusâ€eluting bioresorbable scaffolds in a diabetic allâ€comers population. Catheterization and Cardiovascular Interventions, 2015, 86, 975-981.	1.7	8
568	Coronary procedures in German hospitals: a detailed analysis for specific patient clusters. Clinical Research in Cardiology, 2015, 104, 555-565.	3.3	8
569	Use and outcome of thrombus aspiration in patients with primary PCI for acute ST-elevation myocardial infarction: results from the multinational Euro Heart Survey PCI Registry. Heart and Vessels, 2016, 31, 1438-1445.	1.2	8
570	Relationship Between Peak Troponin Values and Longâ€Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. Journal of the American Heart Association, 2017, 6, .	3.7	8
571	Computed Tomography for Diagnosis andÂClassification of Bicuspid Aortic ValveÂDisease in Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Imaging, 2018, 11, 1539-1540.	5.3	8
572	Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54. Journal of the American Heart Association, 2018, 7, e009260.	3.7	8
573	Fiveâ€year experience with pulmonary vein isolation using the secondâ€generation cryoballoon for treatment of persistent atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2018, 29, 1500-1507.	1.7	8
574	Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome. Clinical Research in Cardiology, 2021, 110, 1353-1368.	3.3	8
575	Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial. American Heart Journal, 2022, 247, 33-41.	2.7	8
576	Unstable angina: Current concepts of medical management. Cardiovascular Drugs and Therapy, 1988, 2, 333-339.	2.6	7

#	Article	IF	Citations
577	Allergy in coronary in-stent restenosis. Lancet, The, 2001, 357, 1206-1207.	13.7	7
578	Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics. Clinical Research in Cardiology, 2010, 99, 375-383.	3.3	7
579	Pre-hospital ultrasound detects pericardial tamponade in young patients with occult blunt trauma: time for preparation? Case report and review of literature. Clinical Research in Cardiology, 2014, 103, 409-411.	3.3	7
580	Reference Values and Release Kinetics of B-Type Natriuretic Peptide Signal Peptide in Patients with Acute Myocardial Infarction. Clinical Chemistry, 2015, 61, 1532-1539.	3.2	7
581	Bioresorbable scaffolds for the treatment of in-stent restenosis. Heart and Vessels, 2015, 30, 265-269.	1.2	7
582	\hat{l}^2 -Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index. Clinical Research in Cardiology, 2016, 105, 527-534.	3.3	7
583	Rescue baroreflex activation therapy after Stanford B aortic dissection due to therapy-refractory hypertension. Journal of the American Society of Hypertension, 2016, 10, 490-492.	2.3	7
584	A new novolimus-eluting bioresorbable scaffold for large coronary arteries: an OCT study of acute mechanical performance. International Journal of Cardiology, 2016, 220, 706-710.	1.7	7
585	Effect of Renal Sympathetic Denervation on Specific Micro (scp) RNA (scp) as an Indicator of Reverse Remodeling Processes in Hypertensive Heart Disease. Journal of Clinical Hypertension, 2016, 18, 497-502.	2.0	7
586	Long-term clinical outcome after implantation of the self-expandable STENTYS stent in a large, multicenter cohort. Coronary Artery Disease, 2017, 28, 588-596.	0.7	7
587	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	7
588	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 158-165.	1.0	7
589	Incidental Finding of Strut Malapposition Is a Predictor of Late and Very Late Thrombosis in Coronary Bioresorbable Scaffolds. Journal of Clinical Medicine, 2019, 8, 580.	2.4	7
590	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 222-230.	3.0	7
591	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 22-30.	3.0	7
592	Estimation of the Acute Myocardial Infarction Onset Time based on Time-Course Acquisitions. Annals of Biomedical Engineering, 2021, 49, 477-486.	2.5	7
593	NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial. American Heart Journal, 2021, 233, 78-85.	2.7	7
594	Initial experience with a novel, modular, minimalistic approach for transfemoral aortic valve implantation. International Journal of Cardiology, 2021, 332, 54-59.	1.7	7

#	Article	IF	CITATIONS
595	Longâ€Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUSâ€TIMI 54 Trial. Journal of the American Heart Association, 2021, 10, e020446.	3.7	7
596	Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R. EuroIntervention, 2017, 13, 1319-1326.	3.2	7
597	A randomised controlled trial of upstream administration of eptifibatide in patients presenting non-ST segment elevation acute coronary syndrome treated with an invasive strategy. EuroIntervention, 2007, 3, 228-234.	3.2	7
598	Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry. EuroIntervention, 2011, 7, 201-208.	3.2	7
599	Biplane transesophageal color Doppler echocardiography for assessment of mitral valve area with mitral inflow jet widths. Journal of the American Society of Echocardiography, 1995, 8, 121-131.	2.8	6
600	Protection of side-branches in coronary lesions with a new stent design., 1998, 45, 456-459.		6
601	Angiographic, intravascular ultrasound, and fractional flow reserve evaluation of direct stenting vs. conventional stenting using BeStent2 in a multicentre randomized trial. European Heart Journal, 2005, 26, 1852-1859.	2.2	6
602	Multiple Episodes of a Transient Global Left Ventricular Dysfunction Reminiscent to Apical Ballooning. Cardiology, 2007, 108, 1-3.	1.4	6
603	Primary stenting of the left main coronary artery with anomalous origin from the right sinus of valsalva. International Journal of Cardiology, 2007, 114, 137-138.	1.7	6
604	Facilitated reperfusion with prehospital glycoprotein Ilb/IIIa inhibition: predictors of complete ST-segment resolution before primary percutaneous coronary intervention in the On-TIME 2 trial. Journal of Electrocardiology, 2011, 44, 42-48.	0.9	6
605	Influence of Renal Sympathetic Denervation on Quality of Life. Journal of Interventional Cardiology, 2013, 26, 536-541.	1.2	6
606	Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions $\hat{a} \in \mathbb{C}$ Implications from early clinical experience during daily practice. Cardiovascular Revascularization Medicine, 2016, 17, 313-317.	0.8	6
607	"Off-Hours―Versus "On-Hours―Presentation in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 2385-2387.	2.8	6
608	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	6
609	Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects. Clinical Research in Cardiology, 2017, 106, 271-279.	3.3	6
610	Uridine Triphosphate Thio Analogues Inhibit Platelet P2Y12 Receptor and Aggregation. International Journal of Molecular Sciences, 2017, 18, 269.	4.1	6
611	Predictors of early scaffold thrombosis. Coronary Artery Disease, 2018, 29, 389-396.	0.7	6
612	Galectinâ€3 and ST2 as predictors of therapeutic success in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1164-1169.	1.8	6

#	Article	IF	CITATIONS
613	Transfemoral implantation of the ACURATE neo prosthesis using a low-profile expandable introducer system: A multicenter registry. International Journal of Cardiology, 2019, 281, 76-81.	1.7	6
614	Predictive value of preprocedural procalcitonin for short- and long-term mortality after transfemoral transcatheter aortic valve implantation. Heart and Vessels, 2019, 34, 1993-2001.	1.2	6
615	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. International Journal of Cardiology, 2019, 278, 217-222.	1.7	6
616	Mid-regional pro-atrial natriuretic peptide and copeptin as indicators of disease severity and therapy response in CTEPH. ERJ Open Research, 2020, 6, 00356-2020.	2.6	6
617	Myeloid-related protein 8/14 and high-sensitivity cardiac troponin I to differentiate type 2 myocardial infarction. International Journal of Cardiology, 2020, 304, 144-147.	1.7	6
618	Predicting 2â€year allâ€cause mortality after contemporary <scp>PCI</scp> : Updating the logistic clinical <scp>SYNTAX</scp> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	1.7	6
619	Right bundle branch block is not associated with worse short- and mid-term outcome after transcatheter aortic valve implantation. PLoS ONE, 2021, 16, e0253332.	2.5	6
620	Osteopontin and galectin-3 as biomarkers of maladaptive right ventricular remodelingÂin pulmonary hypertension. Biomarkers in Medicine, 2021, 15, 1021-1034.	1.4	6
621	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. EuroIntervention, 2020, 16, 634-644.	3.2	6
622	Cryoballoon ablation of atrial fibrillation: How important is the proper selection of patients?. Cardiology Journal, 2015, 22, 194-200.	1.2	6
623	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. JACC: Cardiovascular Interventions, 2022, 15, 282-293.	2.9	6
624	Risk of bleeding after prehospital administration of high dose tirofiban for ST Elevation Myocardial Infarction. International Journal of Cardiology, 2012, 157, 86-90.	1.7	5
625	Outcomes of Atrial Fibrillation Ablation in Patients With Metabolic Syndrome. Journal of the American College of Cardiology, 2013, 61, 109-110.	2.8	5
626	Score Associated with the Outcome after Multiple Ablation Procedures in Patients with Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 682-690.	1.2	5
627	ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMAX ST-segment resolution substudy. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 404-411.	1.0	5
628	Biomarker response and therapy prediction in renal denervation therapy â€" the role of MR-proadrenomedullin in a multicenter approach. Biomarkers, 2017, 22, 225-231.	1.9	5
629	Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart. Journal of Visualized Experiments, 2017, , .	0.3	5
630	Baroreceptor stimulation in a patient with preexisting subcutaneous implantable cardioverter defibrillator. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 90-92.	1,2	5

#	Article	IF	Citations
631	Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials. International Journal of Cardiology, 2018, 250, 49-55.	1.7	5
632	Association of galectin-3 with changes in left ventricular function in recent-onset dilated cardiomyopathy. Biomarkers, 2019, 24, 652-658.	1.9	5
633	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). American Journal of Cardiology, 2019, 124, 1833-1840.	1.6	5
634	Pregnancy-associated plasma protein A $\hat{a}\in$ a new indicator of pulmonary vascular remodeling in chronic thromboembolic pulmonary hypertension?. Respiratory Research, 2020, 21, 204.	3.6	5
635	Association of 25-hydroxy vitamin D level with the blood pressure response to a maximum exercise test among professional indoor athletes. European Journal of Applied Physiology, 2020, 120, 1931-1941.	2.5	5
636	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, E516-E526.	1.7	5
637	The CO-C1f Region of Cardiac Myosin Binding Protein-C Induces Pro-Inflammatory Responses in Fibroblasts via TLR4 Signaling. Cells, 2021, 10, 1326.	4.1	5
638	Exercise hemodynamics in heart failure patients with preserved and mid-range ejection fraction: key role of the right heart. Clinical Research in Cardiology, 2022, 111, 393-405.	3.3	5
639	Influence of coronary stenosis location on diagnostic performance of machine learning-based fractional flow reserve from CT angiography. Journal of Cardiovascular Computed Tomography, 2021, 15, 492-498.	1.3	5
640	Anatomical suitability and off-label use of contemporary transcatheter heart valves. International Journal of Cardiology, 2022, 350, 96-103.	1.7	5
641	Somatostatin Primes Endothelial Cells for Agonist-Induced Hyperpermeability and Angiogenesis In Vitro. International Journal of Molecular Sciences, 2022, 23, 3098.	4.1	5
642	Hemodynamic, antiischemic, and neurohumoral effects of tedisamil and atenolol in patients with coronary artery disease. Cardiovascular Drugs and Therapy, 2000, 14, 511-521.	2.6	4
643	Erratum to "Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation―[Eur Heart J 23 (2002) 1809–1840]. European Heart Journal, 2003, 24, 485.	2.2	4
644	Real-time three-dimensional echocardiographic diagnosis of postmyocardial infarction ventricular septal defect and guidance of transcatheter closure. Heart, 2007, 93, 551-551.	2.9	4
645	Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher Stent Registry. Clinical Research in Cardiology, 2010, 99, 99-106.	3.3	4
646	Pericardial hemangioma vascularized via left anterior descending. Clinical Research in Cardiology, 2010, 99, 405-407.	3.3	4
647	Single-Side Renal Sympathetic Denervation in a Hypertensive Patient With a Single Kidney. American Journal of Kidney Diseases, 2013, 61, 1042-1043.	1.9	4
648	Left circumflex artery-related myocardial infarction: Does ST elevation matter? Results from the Euro Heart Survey PCI registry. International Journal of Cardiology, 2013, 168, 5239-5242.	1.7	4

#	Article	lF	CITATIONS
649	Acute myocardial infarction and inter-hospital transfer. Heart, 2015, 101, 998-999.	2.9	4
650	Immunological markers of frailty predict outcomes beyond current risk scores in aortic stenosis following transcatheter aortic valve replacement: Role of neopterin and tryptophan. IJC Metabolic & Endocrine, 2016, 10, 7-15.	0.5	4
651	Telemetry-assisted early detection of STEMI in patients with atypical symptoms by paramedic-performed 12-lead ECG with subsequent cardiological analysis. European Journal of Emergency Medicine, 2017, 24, 272-276.	1.1	4
652	Overlapping implantation of bioresorbable novolimus-eluting scaffolds: an observational optical coherence tomography study. Heart and Vessels, 2017, 32, 781-789.	1.2	4
653	Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial. American Heart Journal, 2018, 196, 1-8.	2.7	4
654	Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial. Clinical Research in Cardiology, 2018, 107, 1192-1195.	3.3	4
655	Evaluation of cystatin C and neutrophil gelatinaseâ€associated lipocalin as predictors of mortality in patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1474-1479.	1.8	4
656	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clinical Cardiology, 2019, 42, 797-805.	1.8	4
657	Effect of Plaque Composition, Morphology, and Burden on DESolve Novolimus-Eluting Bioresorbable Vascular Scaffold Expansion and Eccentricity — An Optical Coherence Tomography Analysis. Cardiovascular Revascularization Medicine, 2019, 20, 480-484.	0.8	4
658	High-sensitivity cardiac troponin assays: finally ready for prime time?. Nature Reviews Cardiology, 2019, 16, 135-136.	13.7	4
659	Preâ€hospital administration of ticagrelor in diabetic patients with STâ€elevation myocardial infarction undergoing primary angioplasty: A subâ€analysis of the ATLANTIC trial. Catheterization and Cardiovascular Interventions, 2019, 93, E369-E377.	1.7	4
660	Incidence and outcome of peri-procedural cardiogenic shock: results from the international Euro Heart Survey PCI registry. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 120-127.	1.0	4
661	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. International Journal of Cardiology, 2020, 320, 27-34.	1.7	4
662	Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. International Journal of Cardiology, 2020, 312, 42-47.	1.7	4
663	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial. Canadian Journal of Cardiology, 2021, 37, 122-130.	1.7	4
664	Usefulness of updated logistic clinical SYNTAX score based on MIâ€SYNTAX score in patients with STâ€elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2021, 97, E919-E928.	1.7	4
665	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. International Journal of Cardiology, 2021, 324, 30-37.	1.7	4
666	Effects of Statins After Transcatheter Aortic Valve Implantation in Key Patient Populations. Journal of Cardiovascular Pharmacology, 2021, 78, e669-e674.	1.9	4

#	Article	lF	CITATIONS
667	Sometimes earlier may not be better. European Heart Journal, 2016, 37, 3316-3318.	2.2	4
668	Impact of age on the effect of pre-hospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis. EuroIntervention, 2018, 14, 789-797.	3.2	4
669	Cysteineâ€Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute) Tj ETQ Heart Association, 2021, 10, e020488.	q1 1 0.784 3.7	4314 rgBT <mark>(</mark>) 4
670	Intravenous Coronary Angiography with Dichromography using Synchrotron Radiation., 1998,, 22-28.		4
671	Application and Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio in Patients with Ischemic and Non-Ischemic Cardiomyopathy. Diagnostics, 2021, 11, 2188.	2.6	4
672	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120010390.	3.9	4
673	Prognostic impact of secondary prevention after coronary artery bypass grafting—insights from the TiCAB trial. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	4
674	Which standard biomarkers are useful for the evaluation of myocardial injury after pulmonary vein isolation with cryoballoon?. Kardiologia Polska, 2011, 69, 1151-5.	0.6	4
675	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€Eluting Stent Implantation: Perâ€Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	3.7	4
676	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2022, 100, 72-82.	1.7	4
677	Protection of infarcting myocardium by slow channel inhibitors (calcium antagonists). American Journal of Cardiology, 1982, 49, 942.	1.6	3
678	Recovery of myocardial function in the hibernating heart. Cardiovascular Drugs and Therapy, 1992, 6, 281-285.	2.6	3
679	Evidence for sustained platelet activation in patients with early postinfarction angina. Thrombosis Research, 1993, 72, 139-143.	1.7	3
680	Troponin T: A New Marker for Myocardial Cell Injury. Annals of Medicine, 1994, 26, 319-320.	3.8	3
681	Potassium Channel Openers and Blockers in Coronary Artery Disease Comparison to Betablockers and Calcium Antagonists. Herz, 2000, 25, 130-142.	1.1	3
682	Therapeutic efficiency of tirofiban in acute coronary syndromes. Lancet, The, 2000, 355, 930-931.	13.7	3
683	Sirolimus-Eluting Versus Bare-Metal Stents for the Reduction of Coronary Restenosis. Herz, 2007, 32, 650-655.	1.1	3
684	Percutaneous closure of a saphenous vein graft aneurysm being at risk for rupture. Clinical Research in Cardiology, 2008, 97, 187-190.	3.3	3

#	Article	IF	Citations
685	Guidelines for anticoagulant use in acute coronary syndromes. Lancet, The, 2008, 372, 532-533.	13.7	3
686	Response to Letter Regarding Article, "Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk― Circulation, 2009, 119, .	1.6	3
687	Current practice and limitations of dual antiplatelet therapy in acute coronary syndrome. European Heart Journal Supplements, 2009, 11, G4-G8.	0.1	3
688	Transient elevation of NT-pro-BNP as a predictor for myocardial ischemia. Clinical Research in Cardiology, 2010, 99, 857-859.	3.3	3
689	The Impact of Age on Effects of Pre-hospital Initiation of High Bolus Dose of Tirofiban Before Primary Angioplasty for ST-Elevation Myocardial Infarction. Cardiovascular Drugs and Therapy, 2011, 25, 323-330.	2.6	3
690	Troponin: more lessons to learn. European Heart Journal, 2014, 35, 338-340.	2.2	3
691	Cryoballoon Ablation in Young Patients With Lone Paroxysmal Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2014, 67, 558-563.	0.6	3
692	Longâ€term verification of functional and structural renal damage after renal sympathetic denervation. Catheterization and Cardiovascular Interventions, 2016, 87, 1298-1303.	1.7	3
693	Resultados del implante de armazón bioabsorbible deÂeverolimus enÂsegmentos largos atendiendo alÂconcepto deÂsolapamiento deÂarmazones. Revista Espanola De Cardiologia, 2016, 69, 1144-1151.	1.2	3
694	Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population. International Journal of Cardiology, 2017, 244, 49-53.	1.7	3
695	Cardiac Myosin Binding Protein-C Autoantibodies Are Potential Early Indicators of Cardiac Dysfunction andÂPatient Outcome in Acute CoronaryÂSyndrome. JACC Basic To Translational Science, 2017, 2, 122-131.	4.1	3
696	How safe are NOACs compared with phenprocoumon after pulmonary vein isolation with the cryoballoon technique using purse-string suture closure?. International Journal of Cardiology, 2017, 248, 201-207.	1.7	3
697	Optical coherence tomography: influence of contrast concentration on image quality and diagnostic confidence. Heart and Vessels, 2017, 32, 653-659.	1.2	3
698	Early clinical outcomes as a function of use of newer oral P2Y 12 inhibitors versus clopidogrel in the EUROMAX trial. Open Heart, 2017, 4, e000677.	2.3	3
699	Tilt testing and what you should know about it - Experience with 835 consecutive patients with syncope of unknown origin. International Journal of Cardiology, 2018, 258, 90-96.	1.7	3
700	Effect of early tirofiban administration on Nâ€terminal proâ€Bâ€type natriuretic peptide level in patients treated with primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2019, 93, E293-E297.	1.7	3
701	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clinical Research in Cardiology, 2020, 109, 918-929.	3.3	3

Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month
Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A) Tj ETQq0 0 0 rgBT 10 werlock 10 Tf 50 5

#	Article	IF	CITATIONS
703	Prospective validation of an acoustic-based system for the detection of obstructive coronary artery disease in a high-prevalence population. Heart and Vessels, 2021, 36, 1132-1140.	1.2	3
704	Long-Term Survival in Patients with or without Implantable Cardioverter Defibrillator after Transcatheter Aortic Valve Implantation. Journal of Clinical Medicine, 2021, 10, 2929.	2.4	3
705	Exercise Hemodynamic Profiling Is Associated With Outcome in Patients Undergoing Percutaneous Mitral Valve Repair. Circulation: Cardiovascular Interventions, 2021, 14, e010453.	3.9	3
706	Therapeutic Coronary Ultrasound Angioplasty in Patients with Symptomatic Coronary Artery Disease. Developments in Cardiovascular Medicine, 1996, , 241-254.	0.1	3
707	Colour coded blood flow imaging in intravascular ultrasound. British Heart Journal, 2000, 84, 376-376.	2.1	3
708	Noninvasive prediction of pulmonary hemodynamics in chronic thromboembolic pulmonary hypertension by electrocardiogram-gated computed tomography. European Journal of Radiology Open, 2021, 8, 100384.	1.6	3
709	Biomarkers-in-Cardiology 8 RE-VISITED—Consistent Safety of Early Discharge with a Dual Marker Strategy Combining a Normal hs-cTnT with a Normal Copeptin in Low-to-Intermediate Risk Patients with Suspected Acute Coronary Syndrome—A Secondary Analysis of the Randomized Biomarkers-in-Cardiology 8 Trial, Cells, 2022, 11, 211.	4.1	3
710	Major determinants of myocardial injury after pulmonary vein isolation with radiofrequency ablation. Kardiologia Polska, 2012, 70, 549-54.	0.6	3
711	Micro-dislodgement of a self-expanding transcatheter heart valve: Incidence, predictors, and outcomes. International Journal of Cardiology, 2022, 358, 77-82.	1.7	3
712	Initial single-center experience with a new intracoronary stent. International Journal of Cardiovascular Interventions, 1998, 1, 99-103.	0.5	2
713	Angiographic Outcome in Multivessel Disease (GABI II Study) Using New Coronary Device Interventions and Comparison with GABI I Trial Results. Cardiology, 2004, 102, 24-31.	1.4	2
714	Natural Tissue Engineering Inside a Ventricular Septum Defect Occluder. Circulation, 2006, 113, e718-9.	1.6	2
715	Reduction of neointimal hyperplasia in porcine coronary arteries by 2-deoxy-d-glucose. Clinical Research in Cardiology, 2009, 98, 355-361.	3.3	2
716	Bioresorbable scaffolds in daily clinical routine. Current Opinion in Cardiology, 2015, 30, 650-656.	1.8	2
717	German Heart Report 2013. Thoracic and Cardiovascular Surgeon, 2015, 63, 86-96.	1.0	2
718	Barostim Implantation with Ipsilateral Carotid Endarterectomy as a One-Stage Procedure. Annals of Vascular Surgery, 2016, 36, 295.e9-295.e11.	0.9	2
719	Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension. Biomarkers in Medicine, 2016, 10, 841-851.	1.4	2
720	Coronary steal syndrome after left internal mammary bypass in a patient with undiagnosed Takayasu arteritis. Clinical Research in Cardiology, 2017, 106, 388-391.	3.3	2

#	Article	IF	CITATIONS
721	Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. American Heart Journal, 2017, 188, 147-155.	2.7	2
722	Outcome of thrombus aspiration in STEMI patients: a propensity score-adjusted study. Journal of Thrombosis and Thrombolysis, 2018, 45, 240-249.	2.1	2
723	Lessons Learned From the German Aortic Valve Registry. Journal of the American College of Cardiology, 2018, 72, 689-692.	2.8	2
724	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non–ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). American Journal of Cardiology, 2018, 122, 1322-1329.	1.6	2
725	First Experience with the New MitraClip NTR/XTR Device. Structural Heart, 2019, 3, 288-295.	0.6	2
726	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. Canadian Journal of Cardiology, 2020, 36, 747-755.	1.7	2
727	Single versus double use of a suture-based closure device for transfemoral aortic valve implantation. International Journal of Cardiology, 2021, 331, 183-188.	1.7	2
728	Latest Developments in Robotic Percutaneous Coronary Intervention. Surgical Technology International, $0, , .$	0.2	2
729	Acute Mechanical Performance of Magmaris vs. DESolve Bioresorbable Scaffolds in a Real-World Scenario. Frontiers in Cardiovascular Medicine, 2021, 8, 696287.	2.4	2
730	Impact of implantation depth on outcomes of new-generation balloon-expandable transcatheter heart valves. Clinical Research in Cardiology, 2021, 110, 1983-1992.	3.3	2
731	Diagnosis and Treatment of Non–ST-Segment Elevation Acute Coronary Syndromes. , 2011, , 369-384.		2
732	First Transfemoral TAV-in-TAV Implantation of an ACURATE Neo2 Into a Degenerated Lotus Prosthesis. Canadian Journal of Cardiology, 2022, 38, 401-403.	1.7	2
733	Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial. Clinical Research in Cardiology, 2023, 112, 518-528.	3.3	2
734	Guidelines for acute coronary syndrome without ST elevation. Lancet, The, 2002, 359, 1350.	13.7	1
735	Acute aortitis with spinal artery aneurysms detected by contrast enhanced magnetic resonance imaging. Clinical Research in Cardiology, 2009, 98, 59-61.	3.3	1
736	Anticoagulation in percutaneous coronary interventions: no man's land?. European Heart Journal, 2010, 31, 2447-2448.	2.2	1
737	Transapical Coronary Artery Intervention. Circulation: Cardiovascular Interventions, 2012, 5, 446-447.	3.9	1
738	Corrigendum to: †Incremental value of high-sensitive troponin T in addition to the revised cardiac index for peri-operative risk stratification in non-cardiac surgery' [Eur Heart J 2013;34(11): 853-862, doi:10.1093/eurheartj/ehs445]. European Heart Journal, 2013, 34, 1853-1853.	2.2	1

#	Article	IF	CITATIONS
739	The Year in Cardiology 2013: acute coronary syndromes. European Heart Journal, 2014, 35, 349-352.	2.2	1
740	Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1144-1151.	0.6	1
741	Carpal tunnel syndrome following transradial coronary intervention. Clinical Research in Cardiology, 2016, 105, 797-799.	3.3	1
742	Follow-Up (Measurement) of Corrected QT Interval in Adult Patients before and after Lung Transplantation. BioMed Research International, 2017, 2017, 1-5.	1.9	1
743	Intravenous sildenafil acutely improves hemodynamic response to exercise in patients with connective tissue disease. PLoS ONE, 2018, 13, e0203947.	2.5	1
744	PREDICTIVE ABILITY OF THE PARIS RISK SCORE IN ALL-COMERS PATIENTS UNDERGOING PCI WITH DRUG ELUTING STENTS: EXTERNAL VALIDATION IN THE GLOBAL LEADERS STUDY. Journal of the American College of Cardiology, 2019, 73, 245.	2.8	1
745	Identification of acute myocardial infarction in elderly patients using optimized highly sensitive troponin I thresholds. Biomarkers, 2019, 24, 549-555.	1.9	1
746	Ultrasound Diagnosed Rare Partial Nephrectomy Complication. International Journal of Angiology, 2019, 28, 025-027.	0.6	1
747	<i>European Heart Journal //i>, discussion forum. European Heart Journal, 2019, 40, 493-493.</i>	2.2	1
748	Comparison between treatment of "established―versus complex "off-label―coronary lesions with Absorb® bioresorbable scaffold implantation: results from the GABI-R® registry. Clinical Research in Cardiology, 2020, 109, 374-384.	3.3	1
749	Impact of coronary calcification on outcomes after ABSORB scaffold implantation: insights from the GABI-R registry. Coronary Artery Disease, 2020, 31, 578-585.	0.7	1
750	The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial. Atherosclerosis, 2020, 303, 1-7.	0.8	1
751	Does the severity of low-gradient aortic stenosis classified by computed tomography–derived aortic valve calcification determine the outcome of patients after transcatheter aortic valve implantation (TAVI)?. European Radiology, 2021, 31, 549-558.	4.5	1
752	Definition of acute kidney injury impacts prevalence and prognosis in ACS patients undergoing coronary angiography. BMC Cardiovascular Disorders, 2021, 21, 183.	1.7	1
753	External validation of the GRACE risk score 2.0 in the contemporary allâ€comers GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2021, 98, E513-E522.	1.7	1
754	Everolimus eluting bioresorbable vascular scaffolds in patients with acute coronary syndromes: Twoâ€year results from the <scp>Germanâ€Austrian ABSORB</scp> registry. Catheterization and Cardiovascular Interventions, 2021, 98, E564-E570.	1.7	1
755	Predictors of scaffold failure and impact of optimized scaffold implantation technique on outcome: Results from the Germanâ€Austrian ABSORB RegIstRy. Catheterization and Cardiovascular Interventions, 2021, 98, E555-E563.	1.7	1
756	â \in Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMIâ \in ™: a post hoc analysis of the randomized GLOBAL LEADERS trial. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 756-773.	1.0	1

#	Article	IF	CITATIONS
757	Evaluation of Patients for Percutaneous Edge-to-edge Mitral Valve Repair. Journal of Thoracic Imaging, 2021, Publish Ahead of Print, .	1.5	1
758	Outcomes of 10,312 patients treated with everolimus $\hat{\epsilon}$ eluting bioresorbable scaffolds during daily clinical practice $\hat{\epsilon}$ results from the European Absorb Consortium. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	1
759	Optimum Utilisation of Novel Antiplatelet Agents in Clinical Practice. Interventional Cardiology Review, 2014, 9, 164.	1.6	1
760	Clinical presentation does not affect acute mechanical performance of the Novolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography. Postepy W Kardiologii Interwencyjnej, 2021, 17, 272-280.	0.2	1
761	No difference in 30-day outcome and quality of life in transradial versus transfemoral access – Results from the German Austrian ABSORB registry (GABI-R). Cardiovascular Revascularization Medicine, 2021, , .	0.8	1
762	Risk-related short-term clinical outcomes after transcatheter aortic valve implantation and their impact on early mortality: an analysis of claims-based data from Germany. Clinical Research in Cardiology, 2022, 111, 934-943.	3.3	1
763	Automated blood collection to assess the time course of platelet activation in vivo. Thrombosis Research, 1994, 74, 537-541.	1.7	0
764	Recurrent Coronary In-Stent Restenosis: Potential of Membrane-Covered Stents. Journal of Interventional Cardiology, 2000, 13, 167-172.	1.2	0
765	Percutaneous coronary intervention guidelines: new aspects for the interventional treatment of acute coronary syndromes. Country Review Ukraine, 2005, 7, K5-K9.	0.8	0
766	Recurrent angina after complete coronary revascularization. Clinical Research in Cardiology, 2007, 96, 295-298.	3.3	0
767	Antiplatelet Therapy in Acute Coronary Syndrome without ST Elevation. , 0, , 143-163.		0
768	Clinical Decisions in Acute Patients: ACS-POCT-Hypertension and Biomarkers. Conference Papers in Medicine, 2013, 2013, 1-3.	0.6	0
769	First-in-Man Coronary Sinus Lead Stabilization Using a Bioresorbable Vascular Scaffold System. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1518-1519.	4.8	O
770	A true bifurcational stenosis treated with a bioresorbable vascular scaffold and a drugâ€eluting metallic stent: Degradable meets durable. Catheterization and Cardiovascular Interventions, 2015, 85, 1184-1188.	1.7	0
771	Reply. Journal of the American College of Cardiology, 2015, 65, 1718-1719.	2.8	0
772	Friedrich Mohr from the Cardiologist's View: A Visionary Leader in Cardiac Medicine. Thoracic and Cardiovascular Surgeon, 2017, 65, S160-S161.	1.0	0
773	Bioresorbable scaffold implantation in patients with indication for oral anticoagulation: A propensity matched analysis. International Journal of Cardiology, 2017, 231, 73-77.	1.7	0
774	Early discharge and late onset conduction disturbances – A conflict of interest?. International Journal of Cardiology, 2018, 273, 88-89.	1.7	0

#	Article	IF	Citations
775	Identification of the infarct time in patients with acute myocardial infarction., 2019, 2019, 1891-1894.		О
776	Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-Years Results from the GABI-R Registry. Journal of Clinical Medicine, 2019, 8, 767.	2.4	0
777	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y 12 Inhibitor Pretreatment. Circulation: Cardiovascular Interventions, 2019, 12, e007445.	3.9	O
778	OCTâ€assessment of scaffold resorption: Analysis of strut intensity by a new resorption index for polyâ€l â€lactic acid bioresorbable vascular scaffolds. Catheterization and Cardiovascular Interventions, 2019, 94, 928-935.	1.7	0
779	Fractional flow reserve and frequency of PCI in patients with coronary artery disease. Herz, 2020, 45, 752-758.	1.1	0
780	TAVR for mixed aortic valve disease – A good companionship?. International Journal of Cardiology, 2020, 300, 113-114.	1.7	0
781	Two year efficacy and safety of small versus large ABSORB bioresorbable vascular scaffolds of ≇8Âmm device length: A subgroup analysis of the German-Austrian ABSORB RegIstRy (GABI-R). IJC Heart and Vasculature, 2020, 27, 100501.	1.1	0
782	Risk of perioperative coronary stent stenosis or occlusion in patients with previous percutaneous coronary intervention undergoing coronary artery bypass grafting surgery. European Journal of Cardio-thoracic Surgery, 2020, 57, 1122-1129.	1.4	0
783	Fiveâ€year followâ€up of patients who underwent everolimusâ€eluting bioresorbable scaffold implantation. Catheterization and Cardiovascular Interventions, 2021, 97, 56-62.	1.7	0
784	Prognostic impact of echocardiographic mean transvalvular gradients in patients with aortic stenosis and low flow undergoing transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2021, 98, E922-E931.	1.7	0
785	Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention – Insights from the CHAMPION program. American Heart Journal Plus, 2021, 9, 100043.	0.6	0
786	Cardiac biomarkers as indicators of right ventricular dysfunction and recovery in chronic thromboembolic pulmonary hypertension patients after balloon pulmonary angioplasty therapy $\hat{a} \in \hat{a}$ a cardiac magnetic resonance imaging cohort study. Pulmonary Circulation, 2021, 11, 1-10.	1.7	0
787	Cardiovascular risk management in patients with inflammatory arthritis: what is good for the joint is good for the heart and vice versa!. F1000 Medicine Reports, 2010, 2, .	2.9	0
788	Atrial Fibrillation and Renal Disease. Journal of Atrial Fibrillation, 2013, 6, 837.	0.5	0
789	Patienten nach Stentimplantation: Worauf ist zu achten?., 0, , .		O
790	Access route and clinical outcomes after ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing invasive treatment strategy. Cardiovascular Revascularization Medicine, 2022, , .	0.8	0
791	Latest Developments in Robotic Percutaneous Coronary Intervention. Surgical Technology International, 2021, 38, 325-330.	0.2	0
792	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011069.	3.9	0

#	Article	IF	CITATIONS
793	Prognostic Power of Pulmonary Arterial Compliance Is Boosted by a Hemodynamic Unloading Test With Glyceryl Trinitrate in Heart Failure Patients With Post-capillary Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2022, 9, 838898.	2.4	O